GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
1 
CONFIDENTIAL  CLINICAL STUDY PROTOCOL  
Protocol Title:  A Phase 2a, Randomized , Double- Blind , Placebo -Controlled, Multi-
Center Study to Evaluate the Effect of GB001 in Patients with Chronic 
Rhinosinusitis  with or without Nasal Polyps 
Protocol Number:  GB001-2101 
Compound Number:  GB001 
Study Phase:  Phase 2 a 
Short Title:  
Sponsor Name:  [CONTACT_79976]001 in Adult Subjects with Chronic Rhinosinusitis 
GB001, Inc. , a wholly owned subsidiary of Gossamer Bio, Inc. 
Legal Registered 
Address:  [ADDRESS_87146]  
San Diego, CA [ZIP_CODE], [LOCATION_003] 
Regulatory Agency Identifier Number:    
EudraCT : 
         2019-001682-33 
 
Version:  5.0 
Approval Date: 16 April  2020 
 
Confidential 
This document contains proprietary and confidential information of GB001, Inc. Acceptance of 
this document constitutes agreement by [CONTACT_1955][INVESTIGATOR_79945]001, 
Inc. The following exceptions may occur under the condition that the party has agreed to keep 
this information confidential: 1) disclosure of information to the extent necessary to obtain 
informed consent, 2) disclosure of the document to study personnel under your supervision who 
need to know the contents for conducting the study, and 3) disclosure of the document to 
appropriate Institutional Review Boards (IRBs)/Independent Ethics Committees ( IEC). The 
foregoing shall not apply to disclosure required by [CONTACT_1956]; however, 
GB001, Inc. shall be promptly notified of any such disclosure. 

GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
2 
CONFIDENTIAL  SPONSOR ’S AUTHORIZED REPRESEN TATIVE SIGNATURE [CONTACT_79990]
r Bio Services, Inc. on behalf of GB001, Inc, 
a wholly owned subsidiary of Gossamer Bio, Inc. 
 Medical M
onitor name [INVESTIGATOR_1238] c ontact information will be provided separately. 
 

GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
3 
CONFIDENTIAL  INVESTIGATOR AGREEMENT  
GB001-2101: A Phase [ADDRESS_87147] this protocol in accordance with 
ethical pri nciples as outlined in the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) guidelines on Good Clinical Practice, any applicable laws and requirements and any additional conditions mandated by a regulatory authority and/or Institutional Review Board/Independent Ethics Committee (IRB/IEC). 
I acknowledge that I am responsible for the overall study conduct and I agree to personally 
conduct or supervise the described clinical study. 
I agree to ensure that  the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of GB001, Inc.  
 
 
   
Signature  
   
[CONTACT_79991]001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
5 
CONFIDENTIAL  Section # and Name  [CONTACT_79992] -19 pandemic  
Global Change  Minor revisions to text  Administrative clarifications were 
incorporated, and t ypographical 
errors were corrected  
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
6 
CONFIDENTIAL  TABLE OF CONTENTS  
SPONSOR’S AUTHORIZED REPRESENTATIVE SIGNATURE [CONTACT_1783]  ...................................2  
INVESTIGATOR AGREEMENT ...................................................................................................3  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  ............................................4  
1. PROTOCOL SUMMARY ..........................................................................................11  
1.1. Synopsis  ......................................................................................................................11  
1.2. Schema  ........................................................................................................................13  
1.3. Schedule of Activities  .................................................................................................14  
2. INTRODUCTION  ......................................................................................................18  
2.1. Study Rationale ...........................................................................................................18  
2.2. Background .................................................................................................................18  
2.3. Benefit/Risk Assessment  ............................................................................................19  
2.3.1.  GB001 Benefit/Risk Assessment ................................................................................19  
2.3.2.  Study Design Benefit/Risk Assessment ......................................................................[ADDRESS_87148] Administered  ........................................................................30  
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
7 
CONFIDENTIAL  6.2. Preparation/Handling/Storage/Accountability ............................................................[ADDRESS_87149] DISCONTINUATION/WITHDRAWAL  ................................................[ADDRESS_87150] to Follow-up .......................................................................................................35  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................35  
8.1. Efficacy Assessments  .................................................................................................37  
8.1.1.  SNOT -22 .....................................................................................................................37  
8.1.2.  Computer Tomography (CT) ......................................................................................[ADDRESS_87151]: University of Pennsylvania Smell Identification Test (UPSIT)  ..............39  
8.1.6.  CRS Exacerbation  .......................................................................................................40  
8.1.7.  Visual Analog Scale (VAS)  ........................................................................................[ADDRESS_87152] ................42  
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information .......................42  
8.3.2.  Method of Detecting AEs and SAEs ..........................................................................42  
8.3.3.  Follow-up of AEs and SAEs .......................................................................................43  
8.3.4.  Regulatory Reporting Requirements for SAEs ...........................................................43  
8.3.5.  Pregnancy  ...................................................................................................................43  
8.3.6.  Death Events  ...............................................................................................................43  
8.3.7.  Disease- Related Events and/or Disease-Related Outcomes Not Qualifying as 
AEs or SAEs  ...............................................................................................................43  
  
8.4. Treatment of Overdose  ...............................................................................................44  
8.5. Pharmacokinetics  ........................................................................................................44  
8.6. Pharmacodynamics and Biomarkers ...........................................................................45  
8.6.1.  Nasal Biomarker Sample  ............................................................................................45  
8.6.2.  Blood Biomarker Analyses .........................................................................................45  
8.6.3.  RNA Transcriptome Research  ....................................................................................45  
  
8.7. Pharmacogenetics  .......................................................................................................46  
9. STATISTICAL CONSIDERATIONS  .......................................................................46  
9.1. Statistical Hypotheses  .................................................................................................46  
9.2. Sample Size Determination  ........................................................................................46  
9.3. Populations for Analyses  ............................................................................................46  
9.4. Statistical Analyses  .....................................................................................................47  
9.4.1.  Efficacy Analyses  .......................................................................................................47  
[IP_ADDRESS].  Primary Efficacy Analysis  ..........................................................................................47  
[IP_ADDRESS].  Secondary Eff icacy Analysis  ......................................................................................47  
9.4.2.  Safety Analyses  ..........................................................................................................48  
9.5. Interim Analyses  .........................................................................................................48  
10. APPENDICES  ............................................................................................................49  
10.1.  Appendix 1:  Regulatory, Ethical, and Study Oversight Considerations (site 
responsibilities)  ...........................................................................................................49  

GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
9 
CONFIDENTIAL  10.1.1.  Regulatory and Ethical Considerations ......................................................................49  
10.1.2.  Informed Consent Process ..........................................................................................49  
10.1.3.  Data Protection  ...........................................................................................................50  
10.1.4.  Dissemination of Clinical Study Data ........................................................................50  
10.1.5.  Data Quality Assurance  ..............................................................................................50  
10.1.6.  Source Documents ......................................................................................................51  
10.1.7.  Study and Site Closure................................................................................................51  
10.1.8.  Publication Policy  .......................................................................................................52  
10.2.  Appendix 2:  Clinical Laboratory Tests ......................................................................53  
10.3.  Appendix 3:  Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow up, and Reporting ........................................................................[ADDRESS_87153] ..........................................................................................56  
10.3.4.  Recording and Follow Up of Adverse Events and Serious Adverse Events ..............57  
10.3.5.  Reporting of SAEs ......................................................................................................59  
10.4.  Appendix 4:  Contraceptive Guidance and Collection of Pregnancy Information  .................................................................................................................60
 
10.5.  Appendix 5:  Genetics ................................................................................................64  
10.6.  Appendix 6:  Liver Safety - Actions and Follow- up Assessments .............................65  
10.7.  Appendix 7:  Visual Analog scale (VAS) ...................................................................68  
10.8.  Appendix 8:  ACQ-5 Questionnaire ...........................................................................69  
10.9.  Appendix 9:  SNOT- 22 Questionnaire  .......................................................................72  
10.10.  Appendix 10:  Prohibited and Restricted Medications and Treatments .....................74  
10.11.  Appendix 11:  Guidance to Address a Pandemic or Other Global Health Emergencies and Potential Impact on the Clinical Study  ...........................................79
 
10.12.  Appendix 12:  Abbreviations ......................................................................................80  
10.13.  Appendix 13: Protocol Amendment History ..............................................................[ADDRESS_87154] OF TABLES  
Table 1:  Investigational Product Formulation by [CONTACT_22059] .........................................30  
Table 2:  Endoscopic Nasal Polyp Score ...................................................................................39  
Table 3:  Protocol- Required Safety Laboratory Assessments ...................................................53  
Table 4:  Liver Safety Laboratory Assessments  ........................................................................54  
Table 5:  Liver Chemistry Criteria Requiring Additional Monitoring with Possible 
Interruption of Investigational Product .......................................................................65  
Table 6:  Liver Chemistry Criteria Requiring Investigational Product Interruption and 
Additional Monitoring ................................................................................................66  
Table 7:  Prohibited Medications and Treatments  .....................................................................74  
Table 8:  Restricted Medications Associated with an Increased Risk of Liver Injury ..............75  
Table 9:  Prohibited Medications Associated with CYP3A4 Induction or Inhibition ...............76  
Table 10:  Prohibited Food and Herbal Supplements Associated with CYP3A4 
Induction or Inhibition ................................................................................................78  
 
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
11 
CONFIDENTIAL  1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Phase [ADDRESS_87155] of GB001 in patients with chronic rhinosinusitis  with or without nasal polyps 
Short Title:  GB001 in adult subjects with chronic rh inosinusitis  
Rationale: 
GB001 is a highly potent and selective oral prostaglandin D 2 receptor (DP 2) antagonist. DP 2 is 
expressed on a variety of cells implicated in the allergic process  including eosinophils, basophils, 
and epi[INVESTIGATOR_1663]  (Kupczyk, 2017;  Singh, 2017) as well as  Group 2 innate lymphoid cells 
(ILC2 ) and T Helper cell type 2 ( Th2) cells ( Kato, 2019). GB001 is being developed as a once-
daily oral add -on maintenance treatment for  patients with  moderate to severe eosinophilic asthma  
and related diseases . 
The purpose of this Phase 2a study is to evaluate the efficacy, safety, pharmacokinetics  (PK), 
and pharmacodynamics (PD) of GB001 compared with placebo in patients with chronic 
rhinosinusitis with or without bilateral nasal polyp s (NP).  
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
13 
CONFIDENTIAL  Overall Design : 
This is a  Phase 2 a, randomized, double-blind, placebo-controlled, multi- center study to evaluate 
GB001 in pa tients with chronic rhinosinusitis with or without bilateral nasal polyps (NP). 
A schematic of the study design is presented in Section  1.2. All subjects will be maintained on a 
stable background therapy of m ometasone furoate nasal s pray for the duration of the study. 
Number of Subjects : 
This study will randomize approximately [ADDRESS_87156] presence of nasal polyps (chronic rhinosinusitis with 
nasal polyps [CRSwNP]), and approximately [ADDRESS_87157] absence of bilateral NP (chronic rhinosinusitis without nasal polyps [CRSsNP]). 
Intervention Groups and Duration:  
Treatment groups: 
• GB001 40 mg once per day (QD)   
• Matching placebo once per day ( QD) 
Total duration for study participation per subject is 24 weeks (includes  a Screening visit; 
followed by [CONTACT_8622] 4- week s Run- in period to allow for collection of baseline Diary data ; 
a 16- week Double- Blind, Placebo -Controlled period; and 4- week Follow-up period). 
Independent Data Monitoring Committee  (IDMC) : No 
 
1.2. Schema  
 
 
Note: Randomization will be stratified by [CONTACT_1606], the presence or absence of NP (CRSwNP and CRSsNP), and the 
presence or absence of comorbid asthma among CRSwNP subjects. The CRSwNP stratum will consist of approximately [ADDRESS_87158] of approximately 36 subjects.  

GB001, Inc. GB00 1 
Protocol GB001-2101 Versio n 5.0, 16 Apr 2020 
16 
CONFIDENTIAL  Procedure 
Screening Visit  
Randomization  
 
 
Double -Blind 
Placebo -
Controlled Period  
Early Withdrawal 
from Study  
Early 
Discontinuation of 
IP 
Follow -up 
(after W16 or EW 
from study)  
Notes  
Visit  1 2 2.5 3 3.5 4 4.25 4.5 5 6 7 If 
needed  If 
needed  Follow    
up  
Week  -4 to -2 0 1 2 3 4 5 6 8 12 16 If 
needed  If 
needed  20 or 
as 
needed  Every visit window +/ - 3 days 
(except for visit 3 which is +/- 2 
days); The Screening period 
includes up to a 4 weeks Run-in 
period  
Hematology with differential  X X
*       X  X X X X See Appendix 2 (Section 10.2).  
Coagulation test (INR only)   X             See Appendix 2 ( Section 10.2). 
*Includes INR at Visit [ADDRESS_87159] will be reflexively performed 
to confirm the results.  
Clinical chemistry  X X X X X X X X X X X X X X See Appendix 2 (Section  10.2), 
Table 4  and Appendix 6 
(Section  10.6). Includes total bile 
acids at every visit.  
If ALP > 1xULN, include 
fractionation of ALP   
Urina lysis X          X X X  See Appendix 2 ( Section  10.2). 
Nasal mucosal lining fluid sample   X       X  X X X  See Section 8.6.1 .  
Pharmacokinetic (PK) sample      
X   
 X X X X  Subject to record time of last 
morning dose taken at home prior to Week 4, [ADDRESS_87160]-dose.  
Biomarker sample (blood, urine)   X       X  X X X  See Sections  8.6.2  and 8.6.3 .  
RNA transcriptome research   X         X X X  See Section 8.6.3 .  
GB001, Inc. GB00 1 
Protocol GB001-2101 Versio n 5.0, 16 Apr 2020 
17 
CONFIDENTIAL  Procedure 
Screening Visit  
Randomization  
 
 
Double -Blind 
Placebo -
Controlled Period  
Early Withdrawal 
from Study  
Early 
Discontinuation of 
IP 
Follow -up 
(after W16 or EW 
from study)  
Notes  
Visit  1 2 2.5 3 3.5 4 4.25 4.5 5 6 7 If 
needed  If 
needed  Follow    
up  
Week  -4 to -2 0 1 2 3 4 5 6 8 12 16 If 
needed  If 
needed  20 or 
as 
needed  Every visit window +/ - 3 days 
(except for visit 3 which is +/- 2 
days); The Screening period 
includes up to a 4 weeks Run-in 
period  
Pharmacogenetic sample  X
*    
*   
* * *   
 * If consent provided, sample 
can be collected  at any visit 
post-randomization or any bio-
sample used for this purpose; see 
Section  8.7.  
Other Administrative Procedures                 
Dispense investigational product (IP)   X  
  
X   
X X    
 If subject discontinues IP, but 
stays on study, do not dispense IP 
at subsequent visits ( Section 7.1). 
Collect used IP/conduct accountability       X   X X X X    
Dispense MFNS for use as background 
therapy  X X    X   X X X     
Instruct subjects on Diary use, if all 
screening eligibility criteria are met    
<============================>  Eligible subjects enter the Run-in 
period and complete morning and 
evening Diary  until Week 20 . 
Review Diary   X  X  X   X X X X X X  
Complete eCRF  X X X X X X X X X X X X X X  
    Abbreviations:  CRS  = chronic rhinosinusitis; CT  = computed tomography; eCRF  = electronic case report form; EW = early withdrawal; 
IP =investigational product ; MFNS  = mometasone furoate nasal spray; RNA  = ribonucleic acid.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
18 
CONFIDENTIAL  2. INTRODUCTION 
2.1. Study Rationale  
GB001 is a highly potent and selective oral prostaglandin D 2 receptor (DP 2) antagonist. DP 2 is 
expressed on a variety of cells implicated in the allergic process including eosinophils, basophils, 
and epi[INVESTIGATOR_1663]  (Kupczyk , 2017; Singh, 2017) as well as Group 2 innate lymphoid cells 
(ILC2 ) and T Helper cell type 2 ( Th2) cells  (Kato, 2019). GB001 is being developed as a once-
daily oral add -on maintenance treatment for patients  with  moderate to severe eosinophilic asthma  
and related diseases, and for patients with chronic rhinosinusitis with or without nasal polyps 
(NP). 
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and 
pharmacodynamics  (PD) of GB001 compared with placebo in patients with chronic 
rhinosinusitis with or without bilateral NP . 
2.2. Background  
Chronic rhinosinus itis (CRS)  is defined as any inflammatory condition of the paranasal sinuses 
and associated nasal mucosa for more than 12 weeks ( Fokkens, 2007). The loss of epi[INVESTIGATOR_79946], with the loss of tight 
junctions permitting access to the sinus stromal tissue  by [CONTACT_79957], bacteria, and bacteria- derived 
antigens. Clinical symptoms include nasal obstruction and congestion, reduction in or loss of sense of smell, anterior and posterior rhinorrhea, and facial pain. These symptoms can impact greatly upon a patient ’s quality of life.  
Current recommendations for phenotypi[INVESTIGATOR_79947] (chronic rhinosinusitis with nasal polyps [CRSwNP]) or absence of nasal polyps (chronic rhinosinusitis without nasal polyps [CRSsNP]) ( Fokkens, 2007). In a multinational study 
undertaken by [CONTACT_79958], the total prevalence of CRSwNP and CRSsNP has been estimated at 15.5% and 10.9% in the [LOCATION_003] and Europe, respectively ( Collins, 1997; Hastan, 2011). Patients  with CRSwNP  and comorbid asthma (~30%) 
have a poor therapeutic response and a high recurrence rate, and their disease tends to be more resistant to treatment ( Thomas, 2008; Fokkens, 2007).  
Within th e group of patients with aspi[INVESTIGATOR_79948], nasal polyps are found in 36% to 60% of 
patients. Patients with aspi[INVESTIGATOR_79948], asthma, and NP, also known as aspi[INVESTIGATOR_248] -exacerbated 
respi[INVESTIGATOR_3765] (AERD), are usually non- atopic and the disease prevalence increases over the 
age of [ADDRESS_87161] an increased expression of DP
2 (Rothenberg, 2017). 
Eicosanoid changes in paranasal sinus diseases, including AERD, are generally characterized by [CONTACT_79959]-regulation of cysteinyl leukotrienes (CysLTs), lipoxin A4 (LXA4), and prostaglandin D2 (PGD
2) and a down-regulation of cyclooxygenase 2 (COX-2) and prostaglandin E2 (PGE 2).  
Classification of CRS by [CONTACT_79960]- mediated Th2 -high (IL- 4, IL -5, 
and IL-13) cytokine profile. In contrast, CRSsNP is thought to present as a non-eosinophilic 
disease ( Crombruggen, 2011). Emerging data, however,  suggest that NP status alone can often 
be inadequate for defining a Th2-high/IL-5–high eosinophilic phenotype ( Tan, 2017). The Tan  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
19 
CONFIDENTIAL  study examined  tissue concentrations of IL-5 and eosinophil cationic protein (ECP) as surrogate 
marker s for tissue eosinophi lia. While values were significantly greater in patients with 
CRSwNP, there was extensive overlap in ECP concentrations between patients with and without 
NPs. Similarly, in a cluster analysis, expression of IL- [ADDRESS_87162] ers with and without NPs ( Tomassen, 2016).  
Within these two groups, CRSwNP and CRSsNP, patients with an eosinophilic phenotype, 
eosinophilic CRS (e CRS) have a subtype of chronic sinusitis that is thought to occur secondary 
to chronic and systemic eosinophil activation. Patients with eCRS show overlappi[INVESTIGATOR_79949] a poor response to medical and surgical management (Ferguson, 2004). In a recent cross -sectional study of adult patients with CRS  (N = 345) 
undergoing endoscopic sinus surgery, eCRS was defined by [CONTACT_79961] > 10 eosinophils/high-power field on sinus mucosal biopsy. Blood tests were perform ed 
preoperatively and assessed for a full blood count including eosinophils as well as markers of 
inflammation and atopy. Comparisons between eCRS and non- eCRS patients were performed.  
Amon g all cases with  CRS , 60% were  identified as eCRS, of which 41% had  asthma and 47% 
had nasal polyps. Receiver operating characteristic (ROC) curve analysis predicted high tissue eosinophilia at blood eosinophil levels ≥  240 cells/ μL (sensitivity 70.9%, specificity 78.4%, area 
under the curve [AUC]: 0.792, p < 0.01). Th ere was no association with other markers of  
inflammation and  atopy ( Ho, 2018). 
Evidence from treatment with biologics inhibiting Type [ADDRESS_87163] demonstrated 
clinical benefits in patients with CRSwNP  (Bachert, 2017; Bachert , 2016). T he treatment effect 
of GB001 has been demonstrated in patients with asthma  and particularly Type 2 inflammation. 
Specifically, in a Phase 2 study in Japanese subjects (Study PTR-36-201), GB001 reduced asthma worsening (32.7%, GB001 5 mg ; 20.8%, GB001 20 mg) compared with placebo 
(52.8%, p < 0.05 for both dose levels). This effect was enhanced in subjects with eosinophils ≥ 300 cells/ μL.  
In a recent post-hoc analysis of 36 subjects with mild to moderate atopic asthma receiving a total daily dose of fluticasone propi[INVESTIGATOR_16847] ≤ 500 μg or equivalent, who were randomized (2:1) to 30 
mg of GB001 or placebo once daily for 28 days, lung function was analyzed by [CONTACT_79962] (FeNO, < 35 a nd ≥ 35 ppb) and blood eosinophil (< 250 and ≥ 
250/µL) subgroups ( Ortega, 2019; Skolnick, 2019). In the overall population, GB001 had an 
effect on forced expi[INVESTIGATOR_3741] 1 second (FEV1) at Day 28 (difference in mean change for GB001 versus placebo of 102 mL, n = 36). Changes in FEV1 were also observed in the high baseline FeNO (n=14) and high baseline eosinophil (n=1 1) subgroups (differences of 207 mL 
and 133 mL, respectively). These results suggest that GB001 influences lung function in subjects with markers of eosinophilic inflammation.  
It is anticipated that GB001 has the potential to provide clinical benefit in patients with 
eosinophilic chronic rhinosinusitis. 
2.3. Benefit/Risk Assessment  
2.3.1. GB001 Benefit/Risk  Assessment  
GB001, an oral DP [ADDRESS_87164] 1  dose of GB001 at any dose 
level. Of  these, 98 subjects received a single dose of GB001 ranging from 1 mg to 200 mg, and 
361 subjects received multiple doses from 5  mg to 160 mg. Of the 361 subjects who received 
multiple doses, about half (n = 159) were subjects with ast hma in the completed Phase [ADDRESS_87165] 10 mg daily (Study ADC3680-07), or GB001 22.73 mg daily for up to 4 weeks (Study ADC3680-04) or up to 16 weeks concurrent with ICS withdrawal and discontinuation (Study PTR-36-201).  
Based on evaluation of asthma worsening (Study PTR-36-201), GB001 at a [ADDRESS_87166] efficacy in the subgroup of patients with 
eosinophil counts ≥ 300 cells/ μL. This is consistent with the current understanding of the biology 
regarding this pathway.  
As of [ADDRESS_87167] 1 dose of GB001 at any dose 
level. Drug induced liver injury is considered a potential risk of GB001 due to the occurrence of 
two Hy’s Law cases, one was a liver disorder (preferred term) in a healthy subject at 160 mg in Study PTR-36- 101 and one was hepatic enzyme increased (preferred term) in Study 
GB001-[ADDRESS_87168] (OC000459) which  evaluated [ADDRESS_87169] treatment period, there was a significant reduction in the total nasal symptom 
score compared with placebo ( Horak, 2012). These data support the role of DP [ADDRESS_87170] inflammatory disease.   
2.3.2. Study Design Benefit /Risk Assessment  
This study is designed to assess the effect of GB001 on the Sino-N asal Outcome T est-22 
(SNOT -22) in comparison to placebo. 
To minimize any  potential risk to subjects, stringent criteria are utilized during screening to 
exclude subjects with  a history of significant comorbidities that could impact subjects’ safety. 
All participating subjects on active or placebo will be frequently and closely monitored during the study with optimized standard of care.  
This study proposes to minimize the number of subjects to be exposed to GB001, while still 
being able to assess potential effects on CRS disease . Based upon the study design and the close 
monitoring from the Sponsor and/or designee, the bene fits of participation in GB001-[ADDRESS_87171] 
benefit /risk assessment of GB001 in patients with chronic rhinosinusitis with or without bilateral 
nasal polyps.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
22 
CONFIDENTIAL  Objectives  Endpoints  
• To evaluate the effect of GB001 on 
maxillary CT opacification  • Change from baseline to Week [ADDRESS_87172] scan 
• To evaluate the effect of GB001 on worsening of CRS requiring the use of antibiotics  • Prop ortion of subjects with antibiotic use due 
to worsening CRS by [CONTACT_10585] 16 
• To evaluate pharmacokinetics (PK) of GB001 • Plasma concentration of GB001 
• To evaluate the effect of intervention on, as a function of, the pharmacodynamic markers (PD)  • Correlation between baseline markers and 
safety, tolerability, and efficacy parameters  
• Change in PD markers over time 
• To evaluate the relationship between 
safety, efficacy, and exposure parameters and pharmacogenetics  
(PGx) • Correlation between baseline c haracteristics 
and single nucleotide polymorphisms  
• Change from baseline in safety, efficacy, and exposure parameters as a function of 
single nucleotide polymorphisms  
 
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87173] be on a stable regimen of intranasal cortico stero ids (INCS) for 
≥ [ADDRESS_87174] other than mometasone furoate nasal spray 
(MFNS) prior to the Screening visit, the Investigator must switch the subject to MFNS  at the 
Screening visit. All subjects will be maintained on a stable background therapy of m ometasone 
furoate n asal s pray for the duration of the study. 
Screening Visit  (Visit 1): I nformed consent will be obtained, and inclusion and exclusion 
criteria  will be assessed . Informed consent may be obtained prior to the day of the Screening 
visit to allow for medication washouts or for other logistical reasons such as obtaining 
documentation of exacerbations, if necessary. All other screening procedures should be completed , where possible, on the day of the Screening visit. Subjects not meeting the eligibility 
criteria will be deemed screen failures and will not continue participation in the study (see Section  5.4). The Run-in period commences with completion of all  Screening visit procedures 
and concludes at the Randomization visit (V isit 2) . During the Run-in period of up to 4 weeks, 
subjects will capture nasal  symptoms and MFNS use in  a Diary  daily  (morning and evening): 
• Subject’s treatment regimen with MFNS should remain stable . 
• 2 actuations (50 µg/actuation) in each nostril twice daily (total daily dose of 400 µg), unless subject is intolerant to a twice daily ( BID) regimen of MFNS  in which case, 
they can stay on the dose regimen  in place prior to screening . 
• The only dose modification of MFNS during the Run-in period may be for subjects who were switched from another INCS to MFNS and need to change to a QD  
regimen  due to intolerability . 
Randomization Visit ( Day 1/Week  0/Visit 2 ): Subjects who meet the randomization eligibility 
criteria will be randomized in a 1:1  ratio to receive one of the following double- blind treatments 
for 16 weeks:  
• GB001 40 mg once per day (QD)   
• Matching placebo once per day (QD)  
Randomization will be stratified by [CONTACT_1606], the presence or absence of NP  (CRSwNP and 
CRSsNP), and the presence o r absence of comorbid asthma among CRSwNP subjects . Presence 
of NP is defined by a minimum NPS  of [ADDRESS_87175] 2 
for each nostril. Absence of NP is defined as an  absence of NP based on visual examination or an 
NPS of 0 based on nasal endoscopy. Presence of comorbid asthma is defined as a diagnosis of asthma by a physician according to Global Initiative for Asthma  (GINA ) guidelines at  screening  
GB001, Inc. GB001 
Protocol GB001-[ADDRESS_87176] of approximately 36 subjects. 
Subjects will continue on mometasone furoate: MFNS two actuations in each nostril BID (or QD 
in case subject cannot tolerate the high  dose) during the course of the study. 
Following initiation of investigational product (IP) at the clinic, subjects will visit the clinic 
weekly for the first 6 weeks a nd approximately every 4 weeks th ereafter through week 20, for a 
total of 10 additional visits (refer to Schedule of Activities, Section 1.3). 
Early Discontinuation of IP a nd Early Withdrawal from Study:  Subjects will be requested to 
attend the Early Discontinuation of IP or Early Withdrawal (EW) vi sit, as appropriate, and will 
be strongly encouraged to comp lete any remaining study visits as  per the Schedule of Activities 
(SoA; Section 1.3). Subjects who permanently discontinue IP and continue in the study will 
complete the Early Discontinuation of IP visit at the time of IP  discontinuation and then return 
for the next visit in the visit sequence. At the vi sits after the Early Discontinuation of IP visit, 
study procedures will be completed except for di spensation/return of IP . Subjects who withdraw 
early from the study, regardless of the reason, will be requested to return to the clinic to complete 
the EW visit. All subjects who remain on IP  through and including Visit 7 (Week 16) or who 
complete the EW visit will be asked to return for a Follow-up visit approximately [ADDRESS_87177] safety. 
Follow-up Period: Subjects can continue treatment with the stable dose of MFNS maintained 
over the Double-Blind, Placebo-Controlled peri od, or modify treatment based on medical 
judgment.  Total duration for study participation per subject is up to 24 weeks (inclu des a Screening visit, 
followed by [CONTACT_79963] 4-weeks Run-in period to allow for collection of baseline Diary data; 
a 16-week Double-Blind, Placebo-Controlled period; and 4-week Follow-up period). 
4.1.2. Unscheduled Visit 
There may be a need to have a subject return to clinic for an unscheduled visit for a variety of 
reasons, including but not limited to : repeat of a lab test, replacem ent of IP, or evaluation of an 
AE. Any procedure that is conducted during a re gularly scheduled on-treatment visit may be 
performed at an unscheduled visit. 
4.2. Scientific Rationale for Study Design 
4.2.1. Study Population 
The study population is comprise d of: symptomatic CRS subjects with CRSsNP, defined as an 
absence of NP based on visual examination or an NPS of 0 based on nasal endoscopy, and 
evidence of an eosinophilic phenotype (eCRS),  defined as a blood eosinophil count of  ≥ 250 
cells/μL; and symptomatic CRS subjects with CRSwNP,  defined as a minimum NPS of [ADDRESS_87178] of care ( SOC ) 
regimen of mometasone furoate nasal spray (MFNS).  
4.2.2. Choice of Control Group 
All subjects will be on background SOC. The study is placebo- controlled to minimize bias 
and provide an inactive control group to which the efficacy of GB001 can be compared.  
Comparisons between the GB001 and placebo treatment groups will facilitate differentiation of 
the GB001 safety profile from that of the SOC. Lastly, a placebo group, as opposed to an active control, will help to understand whether the occurrence of an AE in the GB001 group is different from that which would occur in this  population in the absence of GB001. 
4.2.3. Efficacy Endpoint Selection 
The primary endpoint is the change from baseline to Week [ADDRESS_87179] of GB001 on bilateral nasal polyps and associated 
sinus symptoms, using specific assessments and questionnaires.  
4.3. Justification for Dose  
This study will assess 40 mg of GB001 in adult subjects with  chronic rhino sinusitis  with or 
without bilateral nasal polyps . In a previous asthma study ( PTR-36-201), GB001 5 mg  and 
20 mg doses were evaluated. While b oth doses of GB001 were effective compared to placebo 
in decreasing the proportion of subjects with asthma worsening/exacerbations in a treatment 
withdrawal design, th e [ADDRESS_87180] (20 mg: 20.8%; 5 mg: 
32.7%; placebo: 52.8%). In addition, only the 20 mg dose demonstrated statistical significance 
for the endpoints of asthma control, Asthma Control Questionnaire (ACQ-5), and time to asthma 
worsening relative to placebo. However , no improvements in lung function were observed, 
suggesting that higher doses are needed to achieve clinical benefit across different endpoints, 
including lung function. A comparable safety profile was observed across all treatment arms 
(including placebo) in this study. Considering that patients with chronic rhinosinusitis with eosinophilic inflammation manifest with more inflammation and disease severity than patients 
with asthma in general, a  dose of [ADDRESS_87181] completed the study if he/she completes the Week [ADDRESS_87182] be met.  
Subjects are eligible to enter the Run -in period only if all of the following criteria are met:  
1. Informed Consent:  Capable of giving signed informed consent which includes 
compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 
2. Age:  ≥ 18 to 75 years of age at the time of Screening visit. 
3. Sex: Males or females : 
a. Women of childbearing pote ntial (WOCBP)  must use an acceptable method of 
contraception ( see Appendix 4, Section  10.4) at least [ADDRESS_87183] dose of IP. 
4. Diagnosis:  Diagnosis of chronic rhinosinusitis with or without bilateral nasal polyps for 
at least 12 week s prior to Visit 1.  
5. Nasal symptoms:  Presence of at least two of the following symptoms prior to Visit 1:  
• nasal blockade/obstruction/congestion  
• nasal discharge (anterior/posterior nasal drip) 
• facial pain/pressure  
• reduction or loss of smell  
6. INCS:  Subjects must be on a stable administration of intranasal corticosteroids (INCS) 
for ≥  2 months prior to Visit 1.  For subjects  using a specialized delivery device (eg, 
XHANCE ™) or corticosteroids administered via irrigation (eg, budesonide + sterile 
saline) , they must be on MFNS for ≥ 2 weeks prior to screening. 
5.2. Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply: 
1. Nasal symptoms: SNOT -22 score < 20 as assessed at screening . 
2. Prior polyp surgery : Subjects who have undergone any nasal surgery ( excluding 
polypectomy performed as an outpatient procedure ) within [ADDRESS_87184] had ≥  [ADDRESS_87185].  
3. Comorbidities:  Presence of a known pre- existing clinically important condition  
including: active tuberculosis, pulmonary fibrosis, bronchopulmonary aspergillosis, eosinophilic granulomatous polyangiitis (Churg-Strauss syndrome), Young’s syndrome, Kartagener’s syndrome or  dyskinetic ciliary syndromes, and cystic fibrosis. C linically 
significant endocrine, autoimmune, metabolic, neurological, renal ( calculated  creatinine 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
27 
CONFIDENTIAL  clearance < 60 mL/min), gastrointestinal, hepatic, cardiovascular, hematological, or any 
other system abnormalities that are uncontrolled with standard treatment.  
4. Malignancy: A current malignancy or previous history of cancer in remission for less than 5 years prior to screening (s ubjects will not be excluded if they had  localized 
carcinoma of the skin that was resected for cure) . 
5. Liver Disease: Known  pre-existing liver disorders (ie, non- alcoholic fatty liver disease 
(NALFD) or Gilbert’s syndrome), or unstable liver disease (as defined by [CONTACT_79964], encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices 
or persistent jaundice), cirrhosis, or known biliary abnormalities . 
6. Prior anti -inflammatory treatment : Subjects who have required a burst of systemic 
corticosteroids ( eg, oral, intravenous, intramuscular corticosteroids) within the [ADDRESS_87186] required intranasal corticosteroid drops within 1 month prior to screening.  
7. Intolerant to mometasone furoate nasal spray. 
8. Specific conditions/concomitant diseases :  Subjects with  conditions such as: 
antrochoanal polyps, nasal septal deviation that would occlude at least one nostril; acute sinusitis, invasive fungal rhinosinusitis, neutrophilic polyposis, nasal infection or upper respi[INVESTIGATOR_79950] 2 weeks before screening. Subjects requiring chronic systemic antibiotic treatment for rhinosinusitis.  
9. Ongoing rhinitis medicamentosa . 
10. ECG Assessment: Subjects with  QTcF ≥ 450 msec  for males or QTcF ≥ [ADDRESS_87187] should be excluded , regardless 
of the average QTcF of the triplicates.
  
11. Alcohol/ Marijuana/Illicit Drugs/Substance Abuse: A known or suspected history of 
alcohol misuse , marijuana,  illicit drugs, or substance abuse within 12 months prior to 
Screening visit.  
12. Smoking history: Asthma  or COPD  patients that are  current smokers  (any substance) , or 
former smokers  with a smoking history of ≥ 10 pack-years [(number of cigarettes per 
day/20) × number of years smoked]. A former smoker is defined as a subject who quit smoking at least 6 months prior to Screening visit. This includes electronic cigarettes and vapi[INVESTIGATOR_007]. 
13. Immunodeficiency: A known immunodeficiency, including that due to human immunodeficiency virus ( HIV), other than that explained by [CONTACT_79965]. 
14. Investigational medications: Subjects who have received treatment with an 
investigational medication within the past 30 days or within 5 half-lives of the 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
28 
CONFIDENTIAL  medication, whichever is longer, prior to Screening visit (t his also includes 
investigational formula tions of marketed products). 
15. Receiving prohibited medications: Refer to Appendix 10 ( Section  10.10)  for more 
details . 
a. Regular use of systemic corticoste roids or immunosuppressive therapi[INVESTIGATOR_79951] 
b. Monoclonal antibodies used in the treatment of asthma   
c. Medications, food or drink that are moderate or strong CYP3A4 inhibitors or inducers  
d. Other m edicati ons that have the potential for interaction with GB001  
e. Medications that have a black -box warning for hepatic toxicity. 
16. Prior participation in a study  with GB001: Subjects who previously participated in 
a study with GB001 ( also named PTR -36 or ADC3680). 
17. Hypersensitivity: A k nown sensitivity to GB001 or any of its excipi[INVESTIGATOR_840]. Subject s with 
rare hereditary problems of galactose intolerance, the Lapp lactase deficiency , 
or glucose- galactose malabsorption . Subjects with mild -moderate lactose intolerance 
are not excluded. Subjects  with  sensitivity  or intolerance to aspi[INVESTIGATOR_248] (ie, subjects with 
aspi[INVESTIGATOR_248] -exacerbated respi[INVESTIGATOR_3765] [ AERD] with or without desensitization ). 
18. Pregnancy: Subjects who are pregnant or breastfeeding. Subject s should not be enrolled 
if they are planning to become pregnant during the time of study participation. A serum 
pregnancy test is required of all females of child -bearing potential at S creening . 
19. Adherence: Subjects who have a known lack of adherence to medications such as INCS . 
20. Body Mass Ind ex (BMI): BMI is  ≥ 40 kg/m2. 
21. Participation : Subject has  any other condition or reason  that, in the opi[INVESTIGATOR_684], would prohibit the subject from participating in the study. 
22. Participation in another clinical study : Subjects  currently participating in an 
interventional clinical study with a biologic agent or who have received study drug in another clinical study are not to be considered for participation until the  completion of the 
safety follow-up visit or following a non- investigational drug period of no less than five 
half-lives . Subjects may not participate in another interventional clinical trial while 
enrolled in this study. 
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87188] fulfill the following criteria to be randomized to study tre atment : 
1. Diary c ompliance: Compliance with completion of the Diary as defined as: 
a. Completion of questions on [ADDRESS_87189] 7 days immediately prior to Visit 2  
(includes the morning of Visit 2). 
b. Note:  If the Diary was completed on < 4 days due to technical challenges, the Visit 2 
may be delayed up to an additional 3 days to allow for completion of the Diary 
parameters above. 
2. Eosinophilic Phenotype:  Subjects must meet at least one of the criteria below. 
• Blood eosinophil count ≥  250 cells/ μL obtained at Visit 1.  
OR 
• Minimum NPS  of [ADDRESS_87190] 2 for each 
nostril as  assessed by a blinded central reader . Subjects with a n NPS  of 1-3 are not 
eligible for randomization.  
3. CRS exacerbation : Subjects who experience a CRS exacerbation during the Run-in 
period should have their Randomization Visit (Visit 2) delayed until the investigator 
considers the subject has returned to their baseline status. If a 4- week Ru n-in period has 
elapsed before the subject is back to baseline status, then the subject will be considered a 
Run- in failure.  CRS exacerbation is defined in Section 8.1.6. 
4. Laboratory abnormality: No evidence of clinically significant abnormality in the hematological, biochemical, or urinalysis at Screening visit, as judged by [CONTACT_093]. 
5. Hepatitis status: No diagnosis of chronic hepatitis B or C, as evidenced by a negative hepatitis B surface antigen (H BsAg) or hepatitis C antibody screen at Screening visit.  
6. Chemistry and hematology obtained at Screening visit:  
• ALT ≤ 1 × the upper limit of normal ( ULN)  
• AST ≤ 1 × ULN  
• Alkaline  phos phatase < 2 × ULN  
• Bilirubin < 1  × ULN  
• Absolute eosinophil count < 1,500 cells /μL 
• White blood cell count < 15,000 cells /μL 
7. Pregnancy test: For WOCBP , both the serum pregnancy test at the Screening visit and 
the urine pregnancy test at Visit [ADDRESS_87191] be negative. 
8. Use of MFNS : Subject newly switched onto MFNS during screening should tolerate  
MFNS during Run-in. 
9. Nasal symptoms: SNOT -22 score ≥ 17 as assessed at randomization . 
10. ECG overread: ECG overread by [CONTACT_79966] F interval is  
< 450 msec for males or QTcF  < [ADDRESS_87192]  number at the time of signing the ICF  and entry  into the 
online registration system (I RT).  Subjects who do not enter the Run- in period will be labeled  as 
screen failures . 
Subjects who enter the Run- in period but are not randomized will be designated as Run- in 
failures , even if they complete the Run-in period.  
A minimal set of S creen failure/Run- in failure  information is required to ensure transparent 
reporting of S creen /Run- in failure subject s to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, S creen /Run- in failure details, eligibility 
criteria, and any serious adverse event  (SAE). 
Subjects who are not randomized may be eligible to rescreen upon approval by [CONTACT_1052]/or designated Medical Monitor. A new subject number will be assigned if approved to rescreen.  One rescreen is permitted.  
6. INVESTIGATIONAL PRODUCT  
6.1. Investigational Product Administered  
 
Table 1: Investigational Product Formulation by [CONTACT_79967]001 40 mg  
 Placebo  
Dose Formulation 20 mg Film -Coated Tablet  Matched  Placebo Film -Coated Tablet  
Unit Dose Strength(s)  2 × 20 mg tablet  2 × placebo tablet  
Dosage Level(s)  40 mg Placebo  
Route of Administration and Instructions  Oral, in the morning 
on an empty stomach
a Oral, in the morning  
on an empty stomacha 
Packaging and Labeling  GB001 and placebo film- coated tablets will be packaged in a blinded manner in 
high-density polyethylene ( HDPE ) 50 mL bottles. The bottles will be labeled as 
required per country requirement. 
Storage Requirements  IP should be stored at room temperature (20–25° C) in the original packaging. 
Protect from moisture.  
IP stored at site will be maintained under controlled, temperature monitored 
conditions. Excursions between 15–30°C are permitted. Any other excursion from 
the required storage condition will be reported to the Sponsor as soon as practical. 
a No food intake. Liquids are acceptable.  
 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
31 
CONFIDENTIAL  6.2. Preparation/Handling/Storage/Accountability  
1. The investigator or designee must confirm appropriate temperature conditions ha ve been 
maintained during transit for all IP received and any discrepancies are reported and 
resolved before use of the IP. 
2. Only subject s enrolled in the study may receive IP and only authorized site staff may 
supply IP . All IP must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.  
3. The investigator, institution, or the head of the medical institution (where applicable) is responsible for IP accountability, reconciliation, and record maintenance ( ie, receipt, 
reconciliation, and final disposition records). 
4. Further guidance and information for the final disposition of IP  are provided in the 
Pharmacy  Manual . 
6.3. Randomization and Blinding  
6.3.1. Randomization 
All subjects will be centrally randomized to IP treatment group using an Interactive Response 
Technology (IRT). Before the study is initiated , directions for use of the system will be provided 
to the sites . 
Randomization will be stratified by [CONTACT_1606], the presence or absence of NP  (CRSwNP and 
CRSsNP), and the presence or absence of comorbid asthma among CRSwNP subjects. Presence 
of NP is defined by a minimum NPS  of [ADDRESS_87193] 2 
for each nostril. Absence of NP is defined as an absence of NP based on visual examination or an 
NPS of 0 based on nasal endoscopy. Presence of comorbid asthma is defined as a diagnosis of 
asthma by a physician according to Global Initiative f or Asthma ( GINA ) guidelines at  screening  
or prior to study entry. The CRSwNP stratum will consist of approximately [ADDRESS_87194]’s randomized treatment group. 
For subsequent visits when IP is dispensed, the IRT system will assign new IP bottle numbers 
based on the subject’s randomized treatment group . 
6.3.3. Unblinding of an Individual S ubject  
The IRT system  will be programmed with blind -breaking instructions. In case of a medical 
emergency, the investigator has the sole responsibility for determining if unblinding of 
a subject ’s treatment assignment is warranted. Subject  safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator, when possible, should make an  effort to contact [CONTACT_79968] a subject ’s treatment assignment, unless this could delay emergency medical 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
33 
CONFIDENTIAL  6.5. Concomitant Therapy  
Subjects should remain on their stable dosing t reatment  (mometasone furoate [eg, NASONEX® 
or a generic such as other mometasone furoate nasal sprays (eg, a s available from  Apotex Corp, 
Amneal Phar maceuticals, LLC, Sandoz Inc) ] 50 micrograms/actuation Nasal Spray ) for the 
duration of their time on study. If a subject discontinues from IP or withdraws from the study due 
to lack of efficacy, SOC therapy should not be adjusted  until after the Safety Follow-up visit. 
Any medication or vaccine (including over- the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the subject  is receiving at the time of enrollment or rece ives 
during the study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates 
• Dosage information including dose and frequency 
The Medical Monitor should be contact[CONTACT_26237]. 
6.5.1. Prohibited and Restricted Medications Prior to the Screening Visit and 
Throughout the S tudy  
Please refer to Appendix 10 ( Section  10.10) for prohibited and restricted  medications  and other 
treatments . 
6.6. Dose Modification  
Dose modifications of IP are not permitted.  Subjects who are unable to  tolerate their  assigned 
dose of IP must be discontinued from IP. 
6.7. Intervention After the End of the Study  
There is no plan for intervention following the end of the study. 
7. DISCONTINUATION OF INVESTIGATIONAL PRODUCT AND 
SUBJECT DISCONTINUATION/ WITHDRAWAL  
7.1. Discontinuation of Investigational Product  
Permanent d iscontinuation of IP does not mean withdrawal from the study, and the subject  will 
be encouraged to remain in the study and continue to complete all study visits and diaries  as per 
the SoA (Section 1.3).  If a subject permanently discontinues IP prior to Visit 6 (Week  12) and 
remains in the study through Visit 7 (Week 16), the subject will not need to return for the 
Follow-up Visit (Week 20) as the Week [ADDRESS_87195] experiences a drug-
induced liver disorder. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
34 
CONFIDENTIAL  For subjects who simultaneously discontinue IP and withdraw early from the study, the EW  Visit 
procedures should be conducted ( Section  1.3), and a separate Early Discontinuation of IP  Visit is 
not needed. The subjects should be encouraged to return for the Follow- up Visit.  
7.1.1. Pregnancy  
A subject must permanently discontinue IP if the subject becomes pregnant. See Appendix 4 
Section  10.4 and S ection 8.3.5 for additional details.  
The Early Discontinuation of IP Visit procedures should be conducted, as shown in the SoA (Section 1.3) , and a separate Early Withdrawal from Study Visit is not needed. 
7.1.2. Liver Safety  
A subject must permanently discontinue IP if the subject meets the liver chemistry criteria that are specified in Appendix [ADDRESS_87196] may withdraw or be withdrawn from the study for the following reasons: 
• Physician  decision  
• Adverse event  
• Noncompliance with study drug  
• Withdrawal by [CONTACT_1130] 
• Study terminated by [CONTACT_1034] 
• Site terminated by [CONTACT_2728] 
• Lost to follow-up 
• Lack of efficacy  
• Pregnancy  
The reason for subject withdrawal from the study will be recorded in the eCRF . 
If a subject is withdraw n from the study and has previously discontinued IP, if possible, the EW 
Visit should be conducted, as shown in the SoA ( Section  1.3). If the subject is simultane ously 
discontinuing IP and withdrawing early from the study, the EW  visit should be conducted. 
The subjects should be encouraged to return for the Follow-up Visit. See SoA  for data to be 
collected at the time of study withdrawal  and at follow -up and for any further evaluations that 
need to be completed . 
If a subject  withdraws from the study, he/she may request destruction of any samples taken and 
not tested , and the investigator must document this in the site study records. 
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87197] fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact [CONTACT_79969] m issed visit as soon as 
possible and counsel the subject  on the importance of maintaining the assigned visit 
schedule and ascertain whether the subject wishes to and/or should continue in the 
study. 
• Before a subject  is deemed lost to follow up, the investigator or designee must make 
every effort to regain conta ct with the subject  (where possible, [ADDRESS_87198] ’s last known mailing address or local 
equivalent methods). These contact [CONTACT_9300] ’s 
medical record . 
• The Sponsor may also attempt to ascertain vital status on  subjects deemed lost to 
follow up. 
• Should the subject  continue to be unreachable, he/she will be considered to have 
withdrawn from the study. The subject’s data and biosamples may still be assayed, in accordanc e with his/her original informed consent. 
8. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA. Protocol waiver s 
or exemptions are not allowed. 
• Safety concerns  should be discussed with the Sponsor immediately upon occurrence 
or awareness to determine if the subject  should continue or discontinue IP. 
• Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct. 
All screening and randomization evaluations must be completed and reviewed to confirm that 
potential subject s meet all eligibility criteria. The Investigator will maintain a log to record 
details of all subjects screened to either confirm eligibility or record reasons for screening 
or Run-in failure s, as applicable.  The suggested order of study procedures should be as follows. 
(Note: this list is not all inclusive. Review the SoA  and the Study Reference Manual for 
additional guidance.) 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
36 
CONFIDENTIAL  Screening Visit (Visit 1) :  
(The list may not be all inclusive. Review the SoA and the Study Reference Manual for 
additional guidance)  
• Informed consent 
• Demography 
• Administer SNOT -22 
• Medical/surgical  history 
• Concomitant medication  review  including confirmation of INCS  use for more than 
8 weeks prior to screening 
• Vital signs  
• Physical exam  including visual exam of nose for polyps 
• 12-lead electrocardiogram  
• Review of inclusion/exclusion criteria 
• Collect urine and blood samples 
• Record a dverse events, if any  
• Dispense Diary and train subject in its use including responding to the morning and evening CRS  symptom questions and daily MFNS use 
• Ensure subject has MFNS ( or equivalent for non- US sites)  for use as required  
background therapy throughout the study. 
• Perform nasal endoscopy (subset of subjects). Endoscopy (including use of 
decongestants and /or anesthetics  before the procedure) will be performed after all 
other efficacy assessments have been completed at each visit; video sequences will be 
downloaded by [CONTACT_79970]’s secure Internet site. For 
eligibility in the CRSwNP stratum, blinded central reading of the Visit 1 endoscopy 
will b e used.  
• Remind patient to bring diary materials to the next visit  
• Complete eCRF  
Note: During the Run-in period, the site should review the central endoscopy overread  report  
and the labor atory results . If the overread or laboratory results indicate that the subject is not 
eligible for randomization, the subject should be contact[CONTACT_79971] . 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
37 
CONFIDENTIAL  Randomization Visit (Visit 2) : 
(The list may not be all inclusive. Review the SoA and the  Study Reference Manual for 
additional guidance)     
• Review Diary to assess eligibility  and remind subject to bring the materials  to the 
next visit 
• Review randomization eligibility criteria  including results from blinded central reader 
of Visit 1 nasal endoscopy to confirm entry criteria 
• Have subject complete questionnaires  including SNOT-22 
• Concomitant medication and adverse event review  
• Vital signs  
• Reconfirm eligibility based on review of Inclusion/Exclusion Criteria ( Section 5.3)  
• Collect lab samples  
• Perform CT scan . If a qualifiable CT scan has been performed within 30 days on the 
qualified equipment consistent with the  study imaging protocol and allowing 
appropriate interpretation/assessment and the image  sequences are available for 
upload to the imaging core laboratory, then a CT  scan  on Vi sit [ADDRESS_87199] be uploaded to the Imaging Core 
Laboratory  at a minimum of 14 days prior to the randomization visit to ensure image 
quality and appropriate quantification. 
• Perform nasal endoscopy (only on subjects  categorized as CRSwNP ) 
• Perform nitric oxide measurement s on all subjects.  
• Dispense IP  
• Complete eCRF  
8.1. Efficacy Assessments 
8.1.1. SNOT -22 
The SNOT -22 (Section  10.9)  is a validated questionnaire to assess the impact of chronic 
rhinosinusitis on quality of life and utilizes a 2-week recall period. I t is a [ADDRESS_87200] of CRS 
on quality of life. A Minimal Clinically Important Difference (MCID ) is available: 8.90  
(Hopkins, 2009).  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
38 
CONFIDENTIAL  8.1.2. Computer Tomography (CT) 
CT of the sinuses will be performed at Randomization, at end of treatment (Visit 7) and if 
a patient is withdrawn early . 
For the accurate assessment of Lund-Mackay scores and 3D volumetric measurement of the maxillary sinus, the same acquisitions (sequences) will be performed and used for centralized 
imaging data assessments and scored  by [CONTACT_79972] .  
Blinded central reading of the Visit [ADDRESS_87201] will be available in a separate operational manual provided to t he sites.  
The Lund-Mackay system is based on localization with points given for degree of opacification: 0 = normal, 1 = partial opacification, 2 = total opacification. These points are then applied to the 
maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The 
osteomeatal complex is graded as 0 = not occluded, or 2 = occluded deriving a maximum score of 12 per side ( Lund, 1993). This scoring system has been validated in several studies 
(Scadding, 2011; Hopkins, 2009).  
For subjects in whom the osteomeatal complex (OC) is missing (because of a previous surgery) the blinded central reader should consider the location of the former OC and provide a scoring 
(as if the OC was there).  
Three- Dimensional volumetric measurement of the maxillary sinus  will be performed at the 
imaging core laboratory. 
This method is used to calculate: 
• volume of the air (mL) 
• volume of mucosa (mL) 
• percent occupi[INVESTIGATOR_79952] 
• thickness of lateral wall  
For the analysis, blinded central reading of the CT at  Visit [ADDRESS_87202]-identifying information from the imaging data header 
prior to sending the imaging data to the imaging core laboratory. The percent change in 
opacification from baseline to end of treatment will be calculated ( Van Agthoven, 2001).  
If
 a prior CT within [ADDRESS_87203] may be acceptable.  
8.1.3. Bilateral Endoscopic Nasal Polyp Score 
The bilateral endoscopic nasal polyp score (NPS) is the sum of the right and left nostril scores, as 
evaluated by [CONTACT_79973], centrally read nasal endoscopy. NP is graded based on polyp size described in the Table 2 below: 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
39 
CONFIDENTIAL  Table 2: Endoscopic Nasal Polyp Score 
Polyp Score  Polyp Size  
[ADDRESS_87204] video se quences 
will be downloaded or sent to the centralized reader. Centralized imaging data assessments and 
scoring by [CONTACT_79974][INVESTIGATOR_014]. To confirm eligibility at V isit 2 (baseline) , only the V isit [ADDRESS_87205]  will use a Diary to:  
Respond to the morning and evening individual rhinosinusitis symptom questions using a 0–3 
categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms) for the following symptoms:  
• congestion and/or obstruction 
• anterior rhinorrhea (runny nose)  
• posterior rhinorrhea (post-nasal drip)  
• loss of sense of smell  
The Diary is provided at Visit 1 and information is collected  on the days /times indicated in the 
Schedule of Activities . Diary entries are to be completed until the Follow-up visit (Week 20).  
The TSS is the sum of the scores from the 4 symptom categories and ranges from 0–12. For each rhinosinusitis symptom category and the TSS, t he average of the available scores recorded 
during the last 7 days before V isit 2 (up to 14 scores, including the morning of Visit 2) will be 
used to determine the baseline value.  A minimum of [ADDRESS_87206] be 
completed (inclusive of the morning entry on the day of randomization) in order to qualify for randomization (see Section 5.3) . 
8.1.5. Smell Test: University of Pennsylvania Smel l Identification Test (UPSIT) 
The test consists of four booklets, each containing 10 odorants with one odorant per page (Doty, 1984). The test -time is about 15 min utes. The stimuli are embedded in 10–[ADDRESS_87207] describes the odor. An UPSIT result is scored out of 40 where a higher 
score indicates better olfaction.   
8.1.6. CRS Exacerbation 
Chronic rhinosinusitis exacerbation  is defined as deterioration of CRS symptoms requiring 
treatment with an  antibiotic, an anti -inflammatory  drug, or a symptom reliever; an Emergency 
Department visit; or hospi[INVESTIGATOR_059] ( Kuiper, 2018; Meltzer, 2006; Rosenfeld, 2015).  
The date of onset of a CRS exacerbation will be considered to be the first date of treatment with an antibiotic, an anti -inflammatory  drug, or a symptom reliever , the date of Emergency 
Department visit, or the date of hospi[INVESTIGATOR_059], whichever occurs first. The end date of 
a CRS  exacerbation will be considered to be the last date of treatment with an  antibiotic, 
an anti-inflammatory  drug , or a symptom reliever , or 6 days after the date of onset  (for a total 
duration of 7 days), whichever is later. Courses of treatment separated by 7 or more days will be 
counted as separate exacerbations.  
8.1.7. Visual Analog S cale ( VAS )  
The visual analog scale (VAS) for rhinosinusitis is used to evaluate the total severity and is only validated in adult CRS to date ( Fokkens, 2007) . The subject  is asked to indicate on a VAS the 
answer to the question: “How troublesome are your symptoms of rhinosinusitis?” The VAS ranks from 0 (Not troublesome) to 10 (Worst thinkable troublesome), see Appendix 7, Section  10.7. 
The disease can be divided into Mild, Moderate, and Severe based on total severity VAS score (0 to 10 cm): 
• Mild = VAS 0 -3 
• Moderate = VAS > 3 –7 
• Severe = VAS > 7–10 
8.1.8. Nitric Oxide  Measurement  
Nitric oxide may be measured at the visits specified in the SoA utilizing equipment provided by a central vendor. Nitric oxide will be measured both by [CONTACT_68058] (fractional exhaled nitric oxide 
[FeNO]) and nasal (nasal nitric  oxide [nNO])  methods . For more details, please refer to the 
Study Reference Manual.  
8.1.9. Other A ssessments 
Asthma control will be assessed at visits (Visits 2, 5, and  7, EW,  early  discontinuation) using 
the ACQ-[ADDRESS_87208] s who reported 
a diagnosis of asthma at the Screening visit.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
41 
CONFIDENTIAL  8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA. 
8.2.1. Physical Examinations 
• A complete physical examination will be conducted as designated in the SoA 
(see Section  1.3). 
• Height and weight will also be measured and recorded as noted in the SoA (see Section 1.3).  
8.2.2. Vital Signs  
• Pulse rate, respi[INVESTIGATOR_697],  temperature, and blood pressure will be assessed. 
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_87209] in a quiet setting without distractions ( eg, television, cell phones). 
• Blood pressure and pulse measurements will be assessed with the subject in a sitting position with a completely automated device. Manual techniques will be used only if an automated device is not available.  
• Vital signs will be measured prior to ECG measurements . 
8.2.3. Electrocardiograms  
• Assessment of a single 12- lead ECG will be obtained as o utlined in the SoA 
(see Section  1.3) to determine heart rate and measure PR, QRS, QT, and QTc 
intervals. The test can be repeated in triplicate if the QTcF value is slightly above the threshold. 
8.2.4. Clinical Safety Laboratory Assessments 
• See Appendix 2 (Se ction 10.2)  for the list of clinical laboratory tests to be performed 
at the visits designated in  the So A. Details for collection, processing and shippi[INVESTIGATOR_79953] a separate Laboratory Manual. 
• The investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the 
eCRF . The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_1173] 's condition. 
• All laboratory tests  with values considered abnormal and clinically significant during 
participation in the study should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_79975]. For ad ditional liver safety monitoring, refer to Appendix 6 
(Section  10.6).  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
42 
CONFIDENTIAL  − If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified,  and the Sponsor 
notified. 
• All protocol-required laboratory assessments, as defined in Appendix 2 
(Section  10.2) , must be conducted in accordance with the Laboratory M anual 
and the SoA.  
• If laboratory values from non-protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in subject  management or are 
considered clinically significant by [CONTACT_093] ( eg, SAE or AE or dose 
modification) , then the resul ts must be recorded in the source document. 
8.3. Adverse Events , Serious Adverse Events , and Adverse Events of 
Interest  
The definitions of an AE, SAE , and AE of Interest  can be found in Appendix 3 ( Section  10.3). 
AE will be reported by [CONTACT_423]  (or, when appropriate, by a caregiver, surrogate, 
or the subject's legally authorized  representative).  
The investigator an d any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE, SAE, or AE of Interest. 
8.3.1. Time Period and Frequency for Collecting AE and SAE Information  
Treatment -emergent adverse events will be collected from the first dose of IP until the end of 
follow up. Serious adverse events will be collected beginning at the time of consent until the end 
of follow up. Medical occurrences that begin after obtaining i nformed consent and before the 
first dose of IP will be recorded on the Medical History/Current Medical Conditions section of the eCRF  and not the AE section. 
All SAEs will be recorded and reported to the Sponsor or designee immediately  upon the site 
learning of an event and under no circumstance should this exceed 24 hours, as indicated in Appendix 3 ( Section  10.3.5) . The investigator will submit any updated SAE data to the Sponsor 
within [ADDRESS_87210] has been discharged from the study, and he/she considers the event to be 
reasonably related to the IP or study participation, the investigator must promptly notify the 
Sponsor. 
8.3.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section 10.3) . 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal questioning of the subject  is the pref erred method to inquire about 
AE occurrences . 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
43 
CONFIDENTIAL  8.3.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each subject  
at subsequent visits/contacts. All SAEs and events of interest (defined in Section  10.3)  will be 
followed until resolution, stabilization, the event is otherwise explained, or the subject  is lost to 
follow up (as defined in Sectio n 7.3) . Further information on follow-up procedures is given in 
Appendix 3 (Section 10.3) . 
8.3.4. Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_29532] a SAE is essential so that 
legal obligations and ethical responsibilities towards the sa fety of subjects and the 
safety of the IP under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of an IP under clinical investigation. 
The Sponsor will comply with country -specific regulatory requirements relating to 
safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators. 
• Investigator safety reports must be prepared for S[LOCATION_003]R according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary. 
• An Investigator who receives an Investigator safety report from the Sponsor 
describing a SAE or other specific safety information ( eg, summary or listing of 
SAEs) will review and then file it along with the IB. The Investigator will then notify 
the IRB/IEC, if appropriate according to local requirements. 
8.3.5. Pregnancy  
• Details of all pregnancies will be collected as outlined in Appendix 4 (Section 10.4) . 
• If a pregnancy is reported, the investigator should inform the Sponsor within 24 hours of learning of the pregnancy and should follow the procedures outlined in Appendix 4 (Section 10.4) . 
• Abnormal pregnancy outcomes ( eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs. 
8.3.6. Death Events  
Timelines for reporting of death events are identical to the requirements for SAE reporting. (Section 10.3.5) . 
8.3.7. Disease -Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs  
CRS exacerbation is an efficacy assessment that is a disease-related outcome not qualifying as an 
AE unless the investigator considers the CRS exacerbation to have met the definition of an SAE 
(Appendix 3; Section  10.3.2) . CRS exacerbation meeting the definition of an SAE will be 
reported in the appropriate eCRF (Appendix 3; Section  10.3.5) . CRS exacerbation not meeting 
the definition of an SAE should not be reported as an AE. CRS exacerbations, as captured by 
[CONTACT_79976]001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
47 
CONFIDENTIAL  • Intent- to-treat (ITT) population: All subjects who are randomized and receive 
at least  one dose of IP, with subjects grouped according to randomized treatment. 
This population will be used for all efficacy analyses. 
• Safety population: All subjects who receive at least [ADDRESS_87211] dose of IP. 
Analyses will generally be performed for the overall population and by [CONTACT_64264] (CRSwNP 
and CRSsNP), other than endpoints associated with outcomes  that are specific to the CRSwNP 
stratum (eg, NPS). 
All statistical hypothesis testing will be at an 0.050 two-sided level of significance.  
9.4.1. Efficacy  Analyses 
[IP_ADDRESS]. Primary Efficacy Analysis 
The primary endpoint of change from baseline to Week 16 in SNOT-22 score will be 
analyzed  by a mixed- effects model with repeated measures (MMRM) using a restricted 
maximum-likelihood (REML)-based approach. The MMRM model will include change from 
baseline scores up to Week 16 as the response variable; the fixed, categorical effects of treatment 
group, randomization strata defined by [CONTACT_79977] 
(ie, CRSwNP with comorbid asthma, CRSwNP without comorbid asthma, and CRSsNP), 
country, visit, and treatment group by [CONTACT_23259]; and the continuous, fixed covariates of 
baseline SNOT -[ADDRESS_87212]- order autoregressive covariance structure will be utilized for the 
primary analysis, based on the covariance structure converging to better fit as determined based 
on Akaike’s information criterion.  
Statistical inference for treatment group comparison of GB001 [ADDRESS_87213] squares 
mean difference, along with the corresponding 95% confidence interval (CI) and p- value.  
[IP_ADDRESS]. Secondary  Efficacy Analysis 
The secondary endpoints of change from baseline to Week 16 in Lund-Mackay total score and in UPSIT score will be analyzed utilizing analysis of covariance (ANCOVA) models including 
covariates for baseline score, presence or absence of bilateral NP, and treatment group.  Results will be presented in terms of least squares mean differences, along with corresponding 95% CI s 
and p- values.  
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87214] for randomization 
strata in the MMRM model defined by [CONTACT_79978] (ie, CRSwNP with 
comorbid asthma and CRSwNP without comorbid asthma) . For NC and  TSS, t he average of the 
scores recorded during the last 7 days before a given visit (14 scores, including the morning of the visit) will be used  to determine the value  for that visit. 
The secondary endpoint of time to first response (≥  1 point improvement from baseline ) in NPS 
will be conducted in the CRSwNP stratum and will be analyzed using a stratified Cox 
proportional hazards model, stratified on the basis of the presence or absence of comorbid 
asthma, adjusted for country, baseline NPS, and treatment group. Subjects without a response 
in NPS will be censored at their last NPS  assessment. The secondary endpoint of time to first 
CRS exacerbation will be analyzed using a stratified Cox proportional hazards model, stratified on the basis of the presence or absence of NP and comorbid asthma (ie, CRSwNP with comorbid asthma, CRSwNP without comorbid asthma, and CRSsNP), adjusted for country and treatment 
group. Subjects without a CRS exacerbation will be censored at their last asses sment for CRS 
exacerbation. Kaplan -Meier estimates and curves will be provided for both time to first response 
in NPS and time to first CRS exacerbation.  
9.4.2. Safet y Analyses 
Safety and tolerability will be examined based on AEs, clinical laboratory results, vital signs, 
and 12-lead ECG assessments.  
Safety analyses will be focused on TEAEs , defined as AEs with onset on or after the first dose of 
IP. The incidence of AEs and SAEs will be summarized by [CONTACT_1570], including the incidence by [CONTACT_6657]. In addition, the incidence of AEs by [CONTACT_926], the incidence of treatment -related AEs, and the incidence of AEs leading to study drug 
discontinuation/study withdrawal will be summarized by [CONTACT_6657]. 
Laborat ory, vital signs, and ECG data will be analyzed by [CONTACT_79979]. The number 
and frequency of subjects with pre- defined abnormalities considered clinically significant will be 
presented. For laboratory parameters, the number and frequency of subjects with shifts from 
baseline to low or high values based on normal ranges will also be presented. 
9.5. Interim Analyses  
No formal interim analyses are planned. 
See Section  6.3.[ADDRESS_87215] of the study to inform further development of GB001.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
49 
CONFIDENTIAL  10. APPENDICES  
10.1. Appendix 1:  Regulator y, Ethical, and Study Oversight 
Considerations (site responsibilities)  
10.1.1. Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
− Applicable ICH Good Clinical Practice (GCP) Guidelines  
− Applicable laws and regulations 
• The protocol, protocol amendments, ICF, IB, Diary  and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated.  
• Any amendments to the protocol wi ll require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subject s. 
• The investigator will be responsible for the following: 
− Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC 
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures 
− Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR  (or equivalent for non -IND sites ), ICH  guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.1.2. Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the subject  or his/her legally authorized representative and answer all questions regarding 
the study. 
• Subject s must be informed that their participation is voluntary. Subject s or their 
legally authorized representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50 (or equivalent for non -IND sites ), 
local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the I RB/IEC or study center. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
50 
CONFIDENTIAL  • The medical  record must include a statement that written informed consent was 
obtained before the subject entered  the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the 
ICF. 
• Subject s must be re-consented to the most current version of the ICF(s) during their 
participation in the study. 
• A copy of the ICF(s) must be provided to the subject  or the subject ’s legally 
authorized representati ve. 
• A pharmacogenetics (PGx) consent form  must be offered to all subjects and the 
process must be documented, unless prohibited by [CONTACT_427]. 
10.1.3. Data Protection 
• Subject s will be assigned a unique identifier by [CONTACT_1034]. Any subject  records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject  
names or any information which would make the subject  identi fiable will not be 
transferred.  
• The subject  must be informed that his/her personal study- related data will be used by 
[CONTACT_9324]. The level of disclosure must also b e explained to the subject . 
• The subject  must be informed that his/her medical records ma y be examined by 
[CONTACT_9325], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
10.1.4. Dissemination of Clinical Study Data 
• A clinical study report (CSR) will be developed by [CONTACT_9327]. This report will be a clinical and statistical integrated report, according to the ICH E3 guidelines. 
• Sponsor will register the study and post study results regardless of outcome on a publicly accessible website in accordance with the applicable laws and regulations.  
10.1.5. Data Quality Assurance 
• All subject  data relating to the study will be recorded on printed or electronic eCRF  
unless transmitted to the Sponsor or designee electronically (eg , labor atory data). 
The investigator is responsible for verifying that data entries are accurate and correct 
by [CONTACT_46388] . 
• The investigator must maintain accurate documentation (source data) that supports the information entered in the e CRF . 
• The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
51 
CONFIDENTIAL  • Monitoring details describing strategy ( eg, risk -based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk-
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site 
monitoring) are provided in the Monitoring Plan. 
• The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (eg, Contract Research Organizations).  
• Study monitors will perform ongoing source data verification to confirm that data 
entered into the eCRF  by [CONTACT_1191], com plete, 
and verifiable from source documents; that the safety and rights of subjects are being 
protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_79980] -GCP and local regulations 
or institutional policies . No records may be destroyed during the retention period 
without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
10.1.6. Source Documents  
• Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected. Source documents are filed at the investigator’s site. 
• Data entered in the eCRF  that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available. 
• Source documents are original documents, data, and records from which the subject’s  
eCRF  data are obtained. These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.  
10.1.7. Study and Site Closure  
• The Sponsor designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the Sponsor . Study sites will be 
closed upon study completion. A study site is considered closed when all required 
documents and study supplies have been collected and a study- site closure visit has 
been performed. 
• The investigator may initiate study -site closure at any time, provided there is 
reasonable cause and sufficient notice is given in advance of the intended termination. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
52 
CONFIDENTIAL  • Reasons for the early closure of a study site by [CONTACT_79981]: 
− Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
− Inadequate recruitment of subject s by [CONTACT_093] 
− Discontinuation of further IP development 
10.1.8. Publication Policy  
• The publication policy is located within the Clinical Study Agreement with the Investigator and/or Institution. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
60 
CONFIDENTIAL  10.4. Appendix 4:  Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions : 
Woman of Childbearing Potential  (WOCBP)  
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile  (see below) . 
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of IP, additional evaluation should be considered. 
Women in the following cate gories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following: 
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the subject’s medical 
records, medical examination, or medical history interview. 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medic al cause.  
− A high follicle stimulating hormone (FSH) level (eg, > 40 IU/L) in the 
postmenopausal range may be used to confirm a postmenopausal state in women 
not using hormonal contraception or hormonal replacement therapy (HRT). However , in the absence of 12 months of amenorrhea, confirmation with more 
than one FSH measurement  is required.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
61 
CONFIDENTIAL  Contracept ion Guidance : 
• A female subject is eligible to participate if she is not pregnant or breastfeeding, 
and at least one of the following conditions applies: 
− Is not a woman of childbearing potential (WOCBP)  
OR 
− Is a WOCBP and using a contraceptive method that is highly effective 
(with  a failure rate of < 1% per year), pref erably with low user dependency 
(see table below ), at least [ADDRESS_87216] dose of IP, and agrees not to donate eggs 
(ova, oocytes) for the purpose of reproduction during this period. The investigator 
should evaluate the effectiveness of the contraceptive method in relationship to the first dose of IP. 
− A WOCBP  must have a negative highly sensitive pregnancy test (urine or serum 
as required by [CONTACT_427]) within [ADDRESS_87217] dose of IP. 
− If a urine test  cannot be confirmed as negative ( eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the subject  must be excluded from 
participation if  the serum pregnancy result is positive. 
Contraceptive use should be consistent with local regulations regarding the use of contraceptive methods for those participating in clinical studies. 
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87218] Low User Dependency  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationb  
• Intrauterine device (IUD) 
• Intrauterine hormone- releasing system (IUS)b 
• Bilateral tubal occlusion  
• Vasectomized partner  
• (Vasectomized partner is a highly effective contraceptive method provided that the partner is the 
sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. 
Spermatogenesis cycle is approximately 90 days.)  
Highly Effective Methodsa That Are User Dependent  
• Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation 
− oral 
− intravaginal 
− transdermal  
− injectable  
• Progestogen- only hormone contraception associated with inhibition of ovulationb 
− oral 
− injectable  
• Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the IP . The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.)  
a Failure rate of < 1% per year when used consistently and correctly. Typi[INVESTIGATOR_17964]  
b If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of action 
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), wi thdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for this study. Male condom and female condom should not be used together (due to risk of failure with friction).  
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87219] ion of Pregnancy Information  
Female Subjec ts who become pregnant  
• The investigator will collect pregnancy information on any female subject  who 
becomes pregnant while participating in this study. Information will be recorded on 
the appropriate form and submitted to the sponsor within [ADDRESS_87220] 's pregnancy.  
• The subject will be followed to determine the outcome of the pregnancy. The investigator will collect follow -up information on the subject and the neonate and the 
information will be forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indicati on for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the 
study intervention by [CONTACT_79982]  10.3.5. While the investigator is not obligated to actively seek this 
information in former study subjects , he or she may learn of an SAE through 
spontaneous reporting. 
• Any female subject who becomes pregnant while par ticipating in the study will 
discontinue IP  or be withdrawn from the study. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
64 
CONFIDENTIAL  10.5. Appendix  5:  Genetics 
Use and Analysis of DNA 
• Genetic variation may impact a subject ’s response to IP , susceptibility to, and severity 
and progression of disease. Variable response to IP may be due to genetic 
determinants that impact drug absorption, distribution, metabolism, and excretion; 
mechanism of action of the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, where local regulations and IRB/IEC allow, a biosample may  be collected for DNA analysis from consenting subject s. 
• DNA samples may  be used for research related to  the relationship between safety, 
efficacy , and exposure parameters collected in this study, as they related to placebo, 
GB001, CRS , and related diseases. They may also be used to develop tests/assays 
including diagnostic tests related to GB001 and DP
2 inhibitors and /or atopic disease.  
• Genetic research may consist of the analysis of candidate polymorphisms, 
prespecified in the statistical analysis plan . 
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to GB001 of this class to understand study disease or related 
atopic conditions. 
• The results of genetic analyses may be reported in a separate study summary.  
• The Sponsor will store the samples in a secure storage space with adequate measures to protect confidentiality.  
• The samples will be retained while research on GB001 continues but no longer than 8 years or other period as per local requirements. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
65 
CONFIDENTIAL  10.6. Appendix 6:  Liver Safety  - Actions and Follow -up Assessments  
Liver chemistry will be evaluated as specified in the SoA (Section  1.3) and Appendix 2 
(Section  10.2) . Parameters will include ALT, AST, GGT, bilirubin , total bile acid s, and ALP.  
For subjects with ALT or AST > 1 × ULN and < 3 × ULN or total bilirubin or direct bilirubin 
> 1 × ULN and ≤ 1.5 × ULN, confirm the value within [ADDRESS_87221] the Medical Monitor to determine the appropriate liver monitoring schedule (eg, weekly or twice a week). 
The criteria requiring additional liver monitoring with possible interruption of study intervention 
are detailed in  Table 5.  
Table 5: Liver Chemistry Criteria Requiring Additional Monitoring with Possible Interruption  of Investigational Product 
Criterion  Actions  
ALT  or AST  ≥ 3 × ULN and <  5 × ULN 
or total bilirubin  or direct bilirubin  > 1.5 
× ULN without symptoms believed to be 
related to liver injury or hypersensitivity, 
and who can be monitored weekly for 4 weeks  • Notify the Medical Monitor  within [ADDRESS_87222] safety.  
“Additional Liver Panel” in Table  6 may  be requested 
by [CONTACT_1689]  
• Confirm values within 24 to 48 hours via repeat labs. If unable to obtain repeat labs within 48 hours, 
discontinue IP . 
• Decision to
 continue or interrupt study intervention 
will be determined by [CONTACT_79983] 
• Subject  must return weekly  or more frequently for 
repeat liver chemistry tests (ALT, AST, GGT, ALP , 
total bile acid s, and bilirubin) until the abnormalities 
resolve, stabilize, or return to baseline. 
• If at any time the subject meets liver chemistry 
interruption criteria  (as specified in  Table 6) , then 
follow the instructions in “Actions and  Follow-up 
Assessments” in  Table  [ADDRESS_87223] ( Section 10.3.3), potential re- challenge will be  restricted  to 
potential DILI cases that have been assessed as unlikely or not related to IP by [CONTACT_79984]. When re-challenging with IP, obtain repeat liver 
chemistries twice weekly  in the first 2 weeks and then weekly for 6 weeks after the re- challenge. 
If there is a rise in liver enzymes > 2 × ULN, the IP should be discontinued permanently . 
The criteria requiring interruption of IP with additional l iver monitoring is detailed in  Table 6.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
66 
CONFIDENTIAL  Table 6: Liver Chemistry Criteria Requiring Investigational Product Interruption 
and Additional Monitoring  
  Liver Chemistry – IP Interruption Criteria  
ALT /AST (single occurrence) ALT  or AST  ≥ 5 × ULN 
ALT /AST  ALT  or AST  ≥ 3 × ULN persists for ≥  4 weeks  
+ Bilirubin a,b ALT  or AST  ≥ 3 × ULN and bilirubin > 2 × ULN (>  35% direct bilirubin)  
+ INR b ALT  or AST  ≥ 3 × ULN and international normalized ratio (INR) >  1.5, if 
INR measured  
+ Cannot Monitor  ALT  or AST  ≥ 3 × ULN and cannot be monitored weekly for 4 weeks  
+ Symptomatic c ALT  or AST  ≥ 3 × ULN associated with symptoms (new or worsening) 
believed to be related to liver injury or hypersensitivity  
Actions and Follow -up Assessments  
Actions  Follow -Up Assessments  
• Immediately discontinue IP 
• Report the event to the Medical Monitor  within 
24 hours  
• Complete the liver event eCRF  and complete a n SAE 
data collection tool if the event also met the criteria 
for an SAEb 
• Perform liver chemistry follow -up assessments. 
• Monitor the subject  until liver chemistry test 
abnormalities resolve, stabilize, or return to baseline (see MONITORING ) 
• Do not restart/rechallenge subject  with IP unless 
Medical Monitor  approval is granted  
• If restart/rechallenge not granted , permanently 
discontinue IP and continue subject  in the study for 
any protocol specified follow up assessments  
 
MONITORING:  
 
• Repeat liver chemistry tests (include ALT, AST, 
GGT, alkaline phosphatase, total bile acids, bilirubin , 
and INR) and perform liver event follow -up 
assessments within 24 hours  
• Monitor subject  twice weekly until liver chemistry 
test abnormalities resolve, stabilize, or return to 
baseline  
• A specialist or hepatology consultation is recommended  
 Additional Liver Panel  
• Viral hepatitis serology
 d 
• Obtain INR and recheck with each liver chemistry assessment until the ALT and/or AST  
values show downward trend  
• Obtain blood sample for pharmacokinetic (PK) analysis  
• Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) 
• Fractionate bilirubin,  if total bilirubin 
> 2 × ULN  
• Obtain complete blood count with differential to assess eosinophilia  
• Record the appearance or worsening of clinical symptoms of liver injury, or hypersensitivity, on the adverse event (AE) report form  
• Record use of concomitant  medications 
(including acetaminophen, herbal remedies, and other over -the-counter medications) on the 
concomitant medications eCRF  
• Record alcohol use on the liver event alcohol intake eCRF  
• Anti- nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney microsomal 
antibodies, and quantitative total immunoglobulin  G (IgG) or gamma globulins  
• Serum acetaminophen assay  
• Liver imaging (ultrasound, magnetic resonance, or computerized tomography) and/or liver biopsy to evaluate liver disease  
a.     Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue IP  if ALT or AST  ≥ 3 × ULN and bilirubin > 2 × ULN. Additionally, if 
serum bilirubin fractionation testing  is unavailable, record the absence/presence of detectable urinary 
bilirubin on dipstick  which is indicative of direct bilirubin elevations suggesting liver injury. 
GB001, Inc.  GB001 
Protocol GB001-[ADDRESS_87224]  ≥ 3 × ULN and bilirubin > 2 × ULN (>  35% direct bilirubin) or ALT  
or AST  ≥ 3 × ULN and INR >  1.5 may indicate severe liver injury (possible ‘Hy’s Law’) and  must be 
reported as  an SAE (excluding studies of hepatic impairment or cirrhosis) . The INR  stated threshold value 
will not apply to subject s receivi ng anticoagulants . INR is not part of routine laboratory assessments in this 
study.  
c.  New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, or jaundice) or hypersensitivity (such as fever, rash , or eosinophilia).  
d. Includes : expanded viral hepatitis serology ( Section 10. 2 Table  4) 
 
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
68 
CONFIDENTIAL 10.7. Appendix 7:  Visual Analog scale (VAS) 
To evaluate the total sever ity, the subject is asked to indicat e on a VAS the answer to the 
question: 
How troublesome are your s ymptoms of rhinosinusitis? 
 
    Not troublesome      W o r s t  t h i n k a b l e  t r o u b l e s o m e  
 Example, not for use. Not to scale. 

GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
69 
CONFIDENTIAL  10.8. Appendix 8:  ACQ -5 Questionnaire  
The ACQ-5 questionnaire is located on the following page. 
$&4&DQDGD(QJOLVK0DSL
$&4B$8BHQJ&$RULGRF$67+0$&[ZIP_CODE]/
48(67,211$,5($&4
6<03720621/<

42/7(&+12/2*,(6/7'
)RUIXUWKHULQIRUPDWLRQ
(OL]DEHWK-XQLSHU0&6306F
3URIHVVRU
0DUFXVH)LHOGV
%RVKDP:HVW6XVVH[321$(QJODQG
7HOHSKRQH
)D[
(PDLOMXQLSHU#TROWHFKFRXN
:HEKWWSZZZTROWHFKFRXN
7KH$VWKPD&RQWURO4XHVWLRQQDLUH $&4LVFRS\ULJKWHGDQGDOOU LJKWVDUH
UHVHUYHG 1RSDUWRIWKLVTXHVWLRQQDLUH PD\EHVROGPRGLILHGRU
UHSURGXFHGL QDQ\IRUPZLWKRXWWKHH[ SUHVVSHUPLVVLRQRI(OL]DEHWK
-XQLSHURQEHKDOIRI42/7HFKQRORJLHV/LPLWHG
'(&(0%(5

7KLVWUDQVODWLRQKDVEHHQPDGHSRVVLEOHWKURXJK
DJUDQWIURP
7UDQVODWHGE\0DSL 
6HQLRU7UDQVODWRU

&21),'(17,$/GB001, Inc. 
Protocol GB001-2101GB001 
Version 5.0, 16 Apr 2020
ASTHMA CONTROL QUESTIONNAIRE©  PATIENT ID : 
(LANGUAGE VERSION  FOR COU NTRY ) 
DATE : 
Page 1 of 1 
ACQ-5 - Canada/English - Mapi. 
ACQ-5_AU1.0_eng-CAori.doc Please answer questions [ADDRESS_87225] week,
how often were you  woken by [CONTACT_79985]?[ADDRESS_87226] week,
how bad were your asthma symptoms
when you woke up  in the morning?[ADDRESS_87227] week, how
limited were yo u in your activities
because of your asthma?[ADDRESS_87228] week, how
much shortness of breath  did you
experience because of your asthma?[ADDRESS_87229] week, how
much of the time did you wheeze ?[ADDRESS_87230] of the time  
6 All the time  
71
CONFIDENTIAL
GB001, Inc. 
Protocol GB001-2101
GB001 
Version 5.0, 16 Apr 2020
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
72 
CONFIDENTIAL  10.9. Appendix 9:  SNOT-22 Questionnaire  
The SNOT -22 questionnaire is located on the following page. 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
79 
CONFIDENTIAL  10.11.  Appendix 11:  Guidance  to Address a Pandemic or Other Global 
Health Emergencies and Potential Impact on the Clinical Study  
In the occurrence of a global health pandemic affecting the conduct of the ongoing study, such as 
the COVID -[ADDRESS_87231] may be adjusted due to subjects being in self-
isolation/quarantine, limited access to public places (including hospi[INVESTIGATOR_600]) due to the risk of spreading infections, and health care professionals being committed to critical tasks ( FDA, 2020; 
EMA, 2020; Health Canada, 2020; MHRA, 2020) . 
Adjustments to the GB001-2101 protocol may be made as described below, in line with global regulatory a uthorities guidance in order to en sure the safety of study participants, maintain 
compliance with  GCP, and minimize the risks to trial integrity during the COVID-19 pandemic 
(FDA, 2020; EMA, 2020; Health Canada, 2020; MHRA, 2020).  Member states within the 
National Competent Authorities may issue their own guidance requiring country specific recommendations to be followed.  
• In the case of missed visits due to COVID -19 (or other health pandemic) related 
reasons:  
− The site should make every effort to contact [CONTACT_79986], and at minimum evaluate AEs/SAEs, concomitant medication s, and the S NOT -[ADDRESS_87232] s tatus .  
− The subject should continue to collect the daily  morning and evening symptom 
diary as described in S ection 8.1.4.  
• Alternative methods of collecting study assessment s may be considered where 
possible: 
− Questionnaires, including SNOT- 22, UPSIT, and ACQ -5, may be self -
administered by [CONTACT_79987]. 
− In certain situations, with Sponsor approval, a local laboratory may be used. 
• Alternative methods of supplying IP to study subjects (eg, direct- to-patient shipment 
from site) may be considered where possible. 
− With prior sponsor approval, IP may be supplied via alternative methods  provided 
that laboratory assessments are able to be performed  prior to the delivery of IP. In 
all cases , study subjects must provide consent for alternative delivery methods. 
Documentation of consent will be captured  in the subject’s study records.  
 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
80 
CONFIDENTIAL  10.12.  Appendix  12:  Abbreviations  
Abbreviation Term  Description  
ACQ-[ADDRESS_87233]  
HRT  hormonal replacement therapy  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee 
IL interleukin (IL-4, IL-5, IL-13) 
ILC2  Group [ADDRESS_87234] 
IRT Interactive Response Technology 
ITT intent- to-treat 
IUD intrauterine device  
IUS intrauterine hormone- releasing system  
LAM  lactational amenorrhoea method  
LDH lactate dehydrogenase  
LXA4  lipoxin A4 
MCID  minimal clinically important difference  
MFNS  mometasone furoate nasal spray  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
82 
CONFIDENTIAL  Abbreviation Term  Description  
MMRM  mixed -effects model with repeated measures  
NAFLD  non-alcoholic fatty liver disease  
NC nasal congestion 
nNO nasal nitric oxide  
NP   nasal polyps 
NPS  nasal polyp score 
OC osteomeatal complex  
PD pharmacodynamic  
PGD 2 prostaglandin D 2 
PGE 2 prostaglandin E2 
PGx pharmacogenetics  
PK pharmacokinetic 
QD once da ily 
QTcF  Fridericia's  correction formula for QT interval (interval between Q wave 
and T wave) 
RBC red blood cell  
REML  restricted maximum -likelihood 
RNA  ribonucleic acid  
SAE  serious adverse event  
SNOT -[ADDRESS_87235]  
VAS  visual analog scale 
WBC white blood cell  
WOCBP  women of childbearing potential 
 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
83 
CONFIDENTIAL  10.13.  Appendix 1 3: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC). 
DOCUMENT HISTORY  
Document  Date  
Amendment 4 (v4.0)  18 Feb 2020 
Amendment 3 (v3.0)  28 Aug 2019 
Amendment 2 (v2.1)  02 May 2019  
Amendment 1 (v2.0.0)  05 Apr 2019  
Original Protocol (v1.0.0)   24 Jan 2019  
Amendment 4  (v4.0; 18 Feb  2020)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to enhance monitoring of liver parameters during the 
conduct of the trial and provide clarification on eligibility  criteria . 
Section # and Name  [CONTACT_9353]  1.3 Schedule of 
Activities;  
Section 1.2  Schema Addition of a Week 1 visit (Visit 
2.5) serum chemistry panel 
following Randomization (Visit 
2). Added CRS exacerbation review at Visits 1, 2, and 2.5.  Week [ADDRESS_87236] month follow ing 
IP initiation. Clarified that CRS exacerbation review is performed 
at every visit.  
Section 4.1.1  Study Design;  
Section 4.2.1 Study 
Population; 
Section 6.3.1  Randomization  Added  visual examination as a 
method of confirming absence of nasal polyps Clarified definition of absence of 
nasal polyps 
Section 5.3  
Randomization Criteria #[ADDRESS_87237] < 2 × ULN to ALT and 
AST ≤ 1 × ULN  Enhance safety characterization 
of the study population 
Section  6.3.[ADDRESS_87238]  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
84 
CONFIDENTIAL  Section # and Name  [CONTACT_9353]  10.6 Appendix 6 : 
Liver Safety - Actions and 
Follow- up Assessments Modified: 
• Discussion of possible 
Investigational Product (IP) continuation or discontinuation if ALT or 
AST ≥  3 × ULN or total 
bilirubin or direct bilirubin > 1.5 × ULN and potential 
triggering of appropriate follow-up to include Liver 
Safety Laboratory assessments  
• ALT or AST > 1 × ULN and 
< 3 × ULN or total bilirubin or direct bilirubin > 1 × ULN and ≤ 1.5 × ULN, confirm the 
value within [ADDRESS_87239] of 
the trial  
 
Global Change  Minor revisions to text  Administrative  updates  were 
incorporated, and typographical 
errors were corrected  
 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
85 
CONFIDENTIAL  Amendment 3  (v3.0; 28 Aug  2019)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to enhance monitoring of liver parameters during the 
conduct of the trial and to provide guidance on drugs that may be associated with hepatoxicity and provide clarification on eligibility  criteria . 
Section # and Name  [CONTACT_9353]  1.3 Schedule of 
Activities;  
Section  1.2 Schema • Notes on t otal bile acid, 
international normalized ratio 
(INR), and fractionation of 
ALP if ALP > 1xULN were 
added. 
• Added assessment of clinical 
chemistry at Week 3.   
• Added separate line for concomitant medications.  
 • Addition of INR 
measurement at baseline. 
Collection of a t otal bile acid    
sample at every visit, and fractionation of ALP if ALP > 1xULN. 
• Week [ADDRESS_87240] 
month following IP initiation. 
• Clarified timing of concomitant medications.  
Section  2.3.1 GB001 
Risk/Benefit Assessment  Revised data for GB001.  Clarified risk/benefit profile.  
Section 5.1  
Inclusion Criterion #2  Maximum  age was increased.  Higher maximum age allowed 
because no additional risk is 
expected in this extended 
population.  
Section 5.2  
Exclusion Criteria #[ADDRESS_87241] from study.  Polypectomy performed as an 
outpatient procedure  is 
considered a minor surgery.  
Section  5.2  
Exclusion Criteria #5   
 Added k nown history of non -
alcoholic fatty liver disease 
(NAFL D) or Gilbert’s Syndrome. Clarified liver -related pre -existing 
conditions. 
Section 5.3  
Randomization Criteria #2  Updated nasal polyp score (NPS) 
range for exclusion from 
randomization.  Clarified that subjects with NPS 
of 0 are eligible for 
randomization.  
Section 5.3  
Randomization Criteria #6   Added maximum a bsolute 
eosinophil count and w hite blood 
cell (WBC)  count criteria.  Enhance safety characterization 
of the study population 
Section  6.5.1  Prohibited 
Medications Prior to the 
Screening Visit and 
Throughout the Study ; • Added the concept of 
restricted medications . 
Referred investigators to list 
of medications in Appendix 
10 which include those  • Increased awareness of 
medications which may 
impact liver effects  and tho se 
drugs/agents that may inhibit 
or induce CYP3A.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
86 
CONFIDENTIAL  Section # and Name  [CONTACT_9353] 10.10  Appendix 10: 
Prohibited Medications and 
Treatments  medications known to have  
the potential for drug induced 
liver injury (DILI) as well as CYP3A inhibitors and 
inducers. 
• Removed XHANCE™ as a 
prohibit ed medication.  • Intranasal corticosteroid 
delivered via a specialized device will be allowed under 
Inclusion Criteria #
6. 
Section  [ADDRESS_87242] nitric oxide measurement.  
Section  8.1.2 Computed 
Tomography (CT) Updated language that prior CT 
may be acceptable under specific 
conditions. Clarification that a prior CT 
within 60 days of the Randomization visit of 
satisfactory quality may be acceptable.  
Section 10.2 Appendix 2: 
Clinical Laboratory Tests Table 3   Total bile acid, INR, and 
fractionation of ALP if ALP > 1xULN were added.  
 To enhance monitoring of liver 
parameters during the conduct of the trial.  
 
Global Change  Minor revisions to text.  Administrative  updates  were 
incorporated, and typographical 
errors were corrected . 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
87 
CONFIDENTIAL  Amendment 2 (v 2.1; 02 May  2019)  
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
because it neither significantly impacts the safety or physical/mental integrity of participants nor the scientific value of the study. 
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to remove assessment of nitric oxide at the Screening 
visit. 
Section # and Name  [CONTACT_9353]  1.3 Schedule of Activities  Remove d assessment of nitric 
oxide at Screening visit. Nasal nitric oxide (nNO) 
and fractional exhaled nitric 
oxide (FeNO) tests are not required at the time of 
screening.  
Section  2.[ADDRESS_87243] . 
Section  8.1.2 Computed Tomography 
(CT)  Updated text to imaging core 
laboratory. Clarification that i maging 
core laboratory will analyze 
CT sequences.  
Section  10.3.[ADDRESS_87244] information  
for sites outside North 
America . 
Global Change  Minor revisions to text.  Admini strative  updates  were 
incorporated, and typographical errors were 
corrected . 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
88 
CONFIDENTIAL  Amendment 1 (v 2.0.0; 5 Apr  2019)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union based 
on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to increase the sample size of the study, include an 
exclusion criterion for AERD, incorporate additional objectives and endpoints, and revise the statistical considerations section to reflect the increased sample size and additional endpoints.  
Section # and Name  [CONTACT_9353]  1.1 Synopsis; 
Section  1.2 Schema;  
Section  4.1.1 Study Design; 
Section  4.2.1 Study Population; 
Section  6.3.1 Randomization; 
Section  9 Statistical Considerations  Total sample size increased to 
100. Added text on randomization and 
stratification.  Increased total number of 
subjects by 30 to enable better characterization of 
benefit- risk profile in 
subjects with nasal polyps. Clarification on 
randomization and 
stratification.  
Section  1.1 Synopsis; 
Section  1.3 Schedule of Activities;  
Section  3 Objectives and Endpoints;  
Section  8.1.9 Other Assessments;  
Section  [IP_ADDRESS] Secondary Efficacy 
Analysis Included additional secondary 
endpoint and clarified 
previous endpoints.  Added and c larified 
secondary endpoints to 
evaluate data including 
exacerbations, time to first 
response in NPS, and change 
in total symptom score to 
better characterize CRS.  
Section  1.[ADDRESS_87245] result.  
Section  1.3 Schedule of Activities; 
Section  4.1.1 Study Design; 
Section  4.2.1 Study Population; 
Section  5.3 Randomization Criteria;  
Section  8 Study Assessments and 
Procedures Added use of mometasone 
furoate nasal spray  (MFNS) 
equivalent. MFNS may not be available 
in some ex -US countries and 
therefore an equivalent 
product may be used. 
Section  3 Objectives and Endpoints   Included additional exploratory endpoints. Added 3 exploratory 
endpoints to further 
understand the role of 
GB001 in CRS.   
Section  4.1.1 Study Design   Written informed consent text was updated. The modification was made 
to clarify that informed 
consent may be obtained prior to Visit 1 to allow fo r 
medication washouts and 
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
89 
CONFIDENTIAL  Section # and Name  [CONTACT_79993].  
Section  4.2.1 Study Population; 
Section  5.2 Exclusion Criteria  Add aspi[INVESTIGATOR_248] -exacerbated 
respi[INVESTIGATOR_3765] (AERD) 
exclusion criterion. Remove subjects with 
AERD to maintain a more 
homogeneous study population. 
Section  5.2 Exclusion Criteria  Text around ECG assessment was updated. This modification was made 
to improve clarity that ECG 
assessment could be 
repeated.  
Section  5.2 Exclusion Criteria  Text was added to exc lude 
smoking of any substance.  This clarification was made 
to include marijuana, its 
components, and any other 
substances which may be 
smoked. 
Section  5.3 Randomization Criteria;  
Section  8 Study Assessments and 
Procedures;  
Section  8.3.7 Disease -Related Events 
and/or Disease- Related Outcomes Not 
Qualifying as AEs or SAEs Added criterion for subjects 
who experience an 
exacerbation. 
Added definition of an 
exacerbation and clarification 
regarding adverse event 
qualification. Clarification on timing of 
randomization for subjects 
who experience an 
exacerbation. Definition was 
added to characterize 
worsening of disease (exacerbations) that may 
occur during the study.  
Section  5.[ADDRESS_87246]; 
Section  9.[ADDRESS_87247] withdrawal from 
study. 
Section  8 Study Assessments and 
Procedures Changed order of assessments Arranged assessments such 
that efficacy assessments 
follow the ordering of 
endpoints. 
Section  8.6.3 RNA Transcriptome 
Research  Text was updated. Clarification that not all samples may be analyzed.  
GB001, Inc.  GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
90 
CONFIDENTIAL  Section # and Name  [CONTACT_9353]  10.10 Appendix 10:  
Prohibited Medications and  
Treatments  Clarification in reference to a 
medication.  Replaced company name 
(Optinose) with trade name 
(XHANCE).  
Global Change Minor revisions to text. Typographical errors were 
corrected.  
 
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
91 
CONFIDENTIAL 11. REFERENCES 
Bachert C, Sousa AR. Lund JV, et al. Reduced need  for surgery in severe  nasal polyposis with 
mepolizumab: Randomized trial. J Allergy Clin Immunol 2017;140:1024-1031. 
Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupi[INVESTIGATOR_79954] l polyposis: a randomized clinical trial. JAMA 
2016;315:469-479. 
Björnsson, ES. Hepatotoxicity by [CONTACT_58084]: The Most  Common Implicated Agents. Int J Mol Sci. 
2016;17(2):224.  
Collins JG. Prevalence of selected chronic c onditions: [LOCATION_002], 1990–1992. Vital Health 
Stat 1997;194:1–89. 
Crombruggen K, Zhang N, Gevaert P, Tomasse n P, Bachert C. Pathogenesis of chronic 
rhinosinusitis: Inflammation. J A llergy Clin Immu nol 2011;128:728-732. 
Doty RL, Shaman P, Kimmelman CP, Dann MS. Univ ersity of Pennsylvani a Smell Identification 
Test: a rapid quantitative olfa ctory function test for the clinic. Laryngoscope 1984;94:176-178. 
EMA, Points to consider on implications of Co ronavirus disease (COV ID-19) on methodological 
aspects of ongoing clinical trials . Amsterdam, The Netherlands: Committee for Human 
Medicinal Products; March 2020. 
FDA, Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation . 
Rockville, MD: Center for Drug Evaluation an d Research, Food and Drug Administration, US 
Dept of Health and Human Services; July 2009.  
FDA, FDA Guidance on Conduct of Clinical Tria ls of Medical Products during COVID-19 
Pandemic. Rockville, MD: Center for Drug Ev aluation and Research, Food and Drug 
Administration, US Dept of Hea lth and Human Services; April 2020 . 
Ferguson BJ. Categorization of eosinophilic chro nic rhinosinusitis. Curr Opin Otolaryngol Head 
Neck Surg 2004;12:237-242. 
Fokkens W, Lund V, Mullol J. European positi on paper on rhinosinusitis  and nasal polyps 2007. 
Rhinol Suppl 2007;20:1-136. Hastan D, Fokkens WJ, Bachert C, et al. Chroni c rhinosinusitis in Europe – an underestimated 
disease. A GA(2)LEN study. Allergy 2011;9:1216–1223. 
Health Canada, Management of clinical trials during th e COVID-19 pandemic: Notice to clinical 
trial sponsors . 2020. https://www.canada.ca/en/health -canada/services/drugs-health-
products/drug-products/announcem ents/management-clinical -trials-during-covid-19-
pandemic.html. Accessed April 13, 2020. 
Ho J, Hamizan WA, Alvarado R, et al. Systemic predictors of eosinophilic chronic rhinosinusitis. 
Am J Rhinol Allergy 2018;32:252-257. 
Hopkins C, Gillett S, Slack R, Lund VJ, Brow ne JP. Psychometric validity of the 22- item 
sinonasal outcome test. Clin  Otolaryngology 2009;34:447-454.  
GB001, Inc. GB001 
Protocol GB001-[ADDRESS_87248] OC000459 
reduces nasal and ocular symptoms in allergic  subjects exposed to gr ass pollen, a randomised, 
placebo-controlled, double-blind trial. Allergy 2012;67:1572–1579. 
Kato A. Group [ADDRESS_87249] 2019;156:141-149. 
Kuiper JR, Hirsch AG, Bandeen-[COMPANY_002] K, et al.  Prevalence, severity, and risk factors for acute 
exacerbations of nasal and sinus symptoms by [CONTACT_79988]. Allergy 
2018;73(6):1244-1253. 
Kupczyk, M. and Kuna, P. Targeting the PGD2 /CRTH2/DP1 Signaling pathway in asthma and 
allergic disease: current  status and future perspectives. Drugs 2017;77:1281-1294 
Lund VJ, Mackay IS. Staging in rh inosinusitus. Rhinology. 1993;31:183-184. 
Meltzer EO1, Hamilos DL, Hadley JA, et al. Rhi nosinusitis: developi[INVESTIGATOR_79955]. J Allergy Clin Immunol 2006;118([ADDRESS_87250]):S17-61. MHRA, Guidance: Managing clinical trials  during Coronavirus (COVID-19).  2020. 
https://www.gov.uk/guidance/managing-clinical-tri als-during-coronavirus-covid-19. Accessed 
April 13, 2020. Ortega H, Fitzgerald M, Bhakta N, Raghupathi K, Singh D. Reduction of exhaled nitric oxide by 
[CONTACT_79989]2 antagonist GB001 in patients with mi ld atopic asthma. J A llergy Clin Immunol. 
2019a;143(2):AB104. Rosenfeld RM, Pi[INVESTIGATOR_79956], Chandrasekhar SS, et al. Clinical practice gu ideline (update): adult 
sinusitis. Otolaryngol Head Neck  Surg 2015;152([ADDRESS_87251]):S1-S39. 
Rothenberg ME, Saito H, Peebles RS. Advances in mechanisms of alle rgic disease in 2016. J 
Allergy Clin Imm unol 2017;140:1622-1631. 
Scadding G, Hellings P, Alobid I, Bachert C, Fokk ens W, Van Wijk RG, et al. Diagnostic tools 
in Rhinology EAACI position paper. Clin Transl Allergy 2011:2;1-39. 
Singh D, Ravi A, Southworth T. CRTH2 antagonists in asthma: current  perspectives. Clin 
Pharmacol 2017;9:165-173. 
Skolnick BE, Ortega H, Raghupathi K, Tompkins C, Fitzgerald M, Singh D. Markers of 
eosinophilic inflammation are asso ciated with response to the DP2 antagonist GB001. American 
Rhinologic Society Annual Meeting; September 13-14, 2019; New Orleans, LA.
 
Tan BK, Klingler AI, Poposki JA, Stevens WW,  Peters AT, Suh LA, et al. Heterogeneous 
inflammatory patterns in chroni c rhinosinusitis without nasal polyps in Chicago, Illinois. J 
Allergy Clin Imm unol 2017;139:699-703. 
Thomas M, Yawn BP, Price D, Lund V, Mullol J, Fokkens W. EPOS Primary Care Guidelines: 
European position paper on the pr imary care diagnosis and management of rhinosinusitis and 
nasal polyps 2007 - a summary. Primary Ca re Respi[INVESTIGATOR_21107] 2008;17:79-89. 
Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory 
endotypes of chronic rhinosinusitis based on clus ter analysis of biomar kers. J Allergy Clin 
Immunol 2016;137:1449-1456. 
GB001, Inc. GB001 
Protocol GB001-2101 Version 5.0, 16 Apr 2020 
93 
CONFIDENTIAL van Agthoven M1, Fokkens WJ, van de Merwe JP , Marijke van Bolhuis E, Uyl-de Groot CA, 
Busschbach JJ. Quality of life of patients with  refractory chronic rhinosinusitis: effects of 
filgrastim treatment. Am J Rhinol. 2001;15:231-237. 
 